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Abstract 
Metabolic syndrome is the clustering of a multitude of cardiometabolic symptoms including 
central obesity, hypertension, insulin resistance, chronic low-grade inflammation and 
dyslipidaemia. Prevalence of metabolic syndrome and obesity is rapidly increasing worldwide, 
which has prompted extensive research into discovering new treatment approaches to prevent 
the growth of this epidemic. The objective for this study was to determine the effectiveness of 
orally administered low (5 mg/kg/day) and high (100 mg/kg/day) doses of curcumin in 
attenuating signs of diet-induced metabolic syndrome in rats. The rat model of obesity used in 
this project, designed by the Functional Foods Research Group at the University of Southern 
Queensland, closely mimics the pathological changes observed in human metabolic syndrome. 
Male Wistar rats (8-9 weeks old) were divided into six experimental groups. In the treatment 
group rats, obesity and signs of metabolic syndrome were developed during the first eight 
weeks of pre-treatment period, followed by curcumin treatment for the remaining eight weeks 
to reverse these symptoms. The total protocol was of 16 weeks. The efficacy of the low and 
high doses of curcumin in attenuating metabolic syndrome was assessed by comparing control 
rats with curcumin treated rats with regard to fat deposition (obesity), cardiovascular health, 
liver function, lipid profile, glucose tolerance and tissue inflammation. The low dose of 
curcumin did not attenuate any signs of obesity. In comparison, the high dose of curcumin was 
able to normalise systolic blood pressure, reduce levels of inflammation in the heart, and lower 
visceral adiposity compared to high-carbohydrate, high-fat diet-fed obese rats. However, the 
high dose of curcumin was unable to affect other components of metabolic syndrome including 
overall fat content, liver health, dyslipidaemia and hyperglycaemia, which conflicted with the 
results of previous studies. Low bioavailability of curcumin may be an important factor in 
unresponsiveness of curcumin in this study and improved bioavailability and reduced 
metabolism through nanoparticles may serve as a future direction for this study. 
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Chapter 1. Introduction and literature review 
 
1.1 What is metabolic syndrome? 
Metabolic syndrome is the clustering of a multitude of cardiometabolic symptoms including 
central obesity, hypertension, insulin resistance, chronic low-grade inflammation and 
atherogenic dyslipidaemia (GrundyKassi et al., 2011). These factors directly increase the risk 
of cardiovascular disease (CVD) and type 2 diabetes, which are two major causes of mortality 
that have been increasing in incidence over the last decade (WHO, 2014). 
There is not one globally accepted definition of metabolic syndrome. Instead, there are 
numerous, often country-specific, definitions of metabolic syndrome which have been used to 
identify those at high risk of developing further complications (Table 1) (Alberti et al., 2009; 
Alberti et al., 2006; Expert Panel on Detection, 2001; Grundy et al., 2004). Across all 
definitions of metabolic syndrome, there appears to be general agreement for the parameter 
thresholds for hyperglycaemia, dyslipidaemia (triglycerides and high-density lipoprotein 
cholesterol (HDL-c) and hypertension. However, definitions developed by the International 
Diabetes Foundation (IDF) and the consensus panel (IDF, National Heart, Lung and Blood 
Institute American Heart Association, World Heart Association, and International Association 
for the Study of Obesity) have included population and country specific thresholds for waist 
circumference (Alberti et al., 2009; Alberti et al., 2006). 
Waist circumference is indicative of central obesity, a phenotype highly correlated with 
metabolic syndrome, although the degree of central obesity has different implications for 
different ethnicities (Alberti et al., 2006). For example, Asian populations have a higher risk 
for the development of metabolic syndrome with a comparatively low waist circumference 
(Alberti et al., 2009). The consensus panel removed central obesity as a compulsory criteria for 
metabolic syndrome in 2009, due to the differences in risk associated with a particular waist 
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measurement between sexes and ethnicities (Alberti et al., 2009). It is expected that an updated 
definition for metabolic syndrome will be developed in the near future; as previous definitions 
are becoming outdated in comparison to the advances in literature regarding obesity and 
metabolic syndrome in the last seven years. 
Table 1. Definitions of metabolic syndrome 
 NCEP ATP III 
(2001) 
AHA/NHLBI 
(2004) 
IDF (2005) 
Consensus panel# 
(2009) 
Criteria Any three of the 
five criteria 
below 
Any three of the 
five criteria 
below 
Central obesity, plus 
two of the four 
criteria 
below 
Any three of the five 
criteria 
below 
Central obesity 
(waist 
circumference) 
Men; >102 cm  
Female; >88 cm 
Men; >102 cm  
Female; >88 cm  
Population and 
country-specific 
definitions 
Population and 
country-specific 
definitions 
Hyperglycaemia 
(fasting glucose) 
≥110 mg/dL$ ≥100 mg/dL ≥100 mg/dL or Rx ≥100 mg/dL or Rx 
Dyslipidaemia 
(triglycerides) 
≥150 mg/dL (1.7 
mmol/L) or Rx* 
≥150 mg/dL (1.7 
mmol/L) or Rx* 
≥150 mg/dL (1.7 
mmol/L) or Rx* 
≥150 mg/dL (1.7 
mmol/L) or Rx* 
Dyslipidaemia 
(HDL-c) 
<40 mg/dL (1.0 
mmol/L) in males; 
<50 mg/dL (1.3 
mmol/L) in 
females or Rx* 
<40 mg/dL (1.0 
mmol/L) in males; 
<50 mg/dL (1.3 
mmol/L) in females 
or Rx* 
<40 mg/dL (1.0 
mmol/L) in males; 
<50 mg/dL (1.3 
mmol/L) in females 
or Rx* 
<40 mg/dL (1.0 
mmol/L) in males; <50 
mg/dL (1.3 mmol/L) in 
females or Rx* 
Hypertension 130/85 mmHg or 
Rx* 
130/85 mmHg or 
Rx* 
≥130/85 mmHg or 
Rx* 
≥130/85 mmHg or Rx* 
*Rx stands for pharmacological treatment 
#Consensus panel includes World Heart Association, International Association for the Study of Obesity, 
IDF, NHBLI, and AHA 
Abbreviations used: NCEP ATP III, National Cholesterol Education Program Adult Treatment Panel 
III; AHA, American Heart Association; NHLBI, National Heart, Lung, and Blood Institute; IDF, 
International Diabetes Foundation; HDL-c, high-density lipoprotein cholesterol. 
$Updated in 2003 to become 100 mg/dL in response to the American Diabetes Association changing 
the criteria for impaired fasting glucose tolerance from 110 mg/dL to 100 mg/dL. 
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1.1.1 What is obesity? 
Obesity is a disorder characterised by a chronic energy imbalance, whereby energy expenditure 
is consistently lower than energy intake, necessitating the expansion of adipose tissue to allow 
the storage of excess energy (Ahn et al., 2010). Obesity is increasing in prevalence at a fast rate 
due to the rapidly increasing adoption of diets rich in saturated fats and simple carbohydrates, 
in combination with a sedentary lifestyle (McGill, 2014). However, the variation in individual 
response to an obesity-inducing environment indicates that there are also clear genetic factors 
involved in determining susceptibility to obesity (El-Sayed Moustafa and Froguel, 2013). The 
World Health Organisation (WHO) reported that in 2014, 39% of adults aged 18 years and 
older were overweight and 13% were obese worldwide (WHO, 2015). The prevalence is 
significantly higher in countries such as the USA, Australia, Canada and Middle Eastern 
countries where obesity prevalence is as high as 30% in the population over the age of 18 years 
(WHO, 2015). Multiple institutions in Australia, such as Medibank Health Solutions, have 
estimated the cost of obesity to range from $30 to $50 billion in Australia in 2012 (Smeerdijk 
et al., 2015), with much higher estimates of $147 billion cost in the USA in 2008 (CDC, 2015). 
With increases in the prevalence of obesity and metabolic syndrome, health costs are 
continuing to rise globally, increasing the burden on the society. 
In a healthy individual, adipose tissue is responsible for maintaining energy homeostasis in 
response to fluctuations in nutrient supply (Choe et al., 2016). In an obese person, there are 
large demands placed on adipose tissue for the storage of excess energy as lipids that 
necessitates adipocyte hypertrophy (increase in size of adipocytes or fat storing cells) and 
hyperplasia (increase in number of adipocytes) (Sun et al., 2011b). Healthy adipose tissue 
expansion features enhanced recruitment of adipocyte precursor cells (hyperplasia) and 
appropriate levels of vascularisation and extracellular matrix growth (Sun et al., 2011a), 
whereas pathogenic expansion is characterised by rapid expansion of existing fat cells 
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(hypertrophy), a high degree of macrophage infiltration, adipocyte death, limited vasculature 
and large amounts of fibrosis (Sun et al., 2011a). In response to further growth beyond the 
expansion limit, adipose tissue expansion that was previously healthy can transition into this 
pathogenic phenotype (Sun et al., 2011a). This pathogenic expansion of adipose tissue leads to 
chronic inflammation, oxidative stress and systemic insulin resistance (Choe et al., 2016; Sun 
et al., 2011a; Trayhurn, 2013). These pathogenic factors favour the development of adipocyte 
dysfunction and consequent deregulation of adipokine (chemical messengers secreted from 
adipocytes) secretion (Trayhurn, 2013). 
Adipose tissue secretes a large number of adipokines including leptin, adiponectin, 
angiotensinogen, interleukin 6 (IL-6) and tumour necrosis factor-alpha (TNF-α) which regulate 
energy balance, insulin sensitivity and carbohydrate and lipid metabolism, blood pressure and 
inflammation, respectively (Wood et al., 2009). There is increased synthesis of the pro-
inflammatory cytokines IL-6 and TNF-α in obesity, which have been found to have important 
roles in furthering the progression of insulin resistance and chronic low-grade inflammation 
(Tchernof and Després, 2013). Whereas the level of adiponectin, which is responsible for 
improving insulin sensitivity, increasing fatty acid oxidation in both liver and muscle tissue 
and enhancing uptake of glucose by muscles, is decreased in obesity (Hajer et al., 2008). 
Whilst it is evident that obesity has the potential to progress to metabolic syndrome, the 
distribution of body fat has a large role in determining metabolic syndrome risk (Maury and 
Brichard, 2010). Accumulation of excess adipose tissue in the intra-abdominal region (visceral 
adipose tissue) is strongly correlated with incidence of metabolic syndrome (Ritchie and 
Connell, 2007). The mechanism responsible for this occurrence is not completely understood, 
however, it has been observed across multiple studies that visceral adipose tissue is associated 
with enhanced monocyte infiltration rate, decreased adiponectin synthesis and increased IL-6 
synthesis (Cancello et al., 2006; Fontana et al., 2007; Tankó et al., 2004).  
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1.1.2 Cardiovascular disease 
The presence of metabolic syndrome is highly indicative of an increased risk of CVD 
regardless of whether the patient is overweight or not, although a higher body mass index 
correlates with a higher risk of CVD (Ärnlöv et al., 2010). Cardiovascular disease is the 
outcome of deleterious changes to the heart and blood vessels that affect the transport of blood 
throughout the body. Restriction of the flow of blood to critical areas such as the heart and 
brain, as in myocardial infarction and stroke, leads to the death of tissue and possible fatality 
(Hanson et al., 2013). The different components of metabolic syndrome all have adverse effects 
on the endothelium of blood vessels, which has a protective role in preventing the development 
of atherosclerosis (Huang, 2009). Atherosclerosis, one of the major mechanisms in the 
development of cardiovascular disease, contributes to changes that occur in the blood vessels, 
and refers to the formation of a plaque in the arterial wall (Lusis, 2000). The role of low-density 
lipoprotein cholesterol (LDL-c) in the formation of plaques vulnerable to rupture (major 
cardiovascular event) is well documented (Bentzon et al., 2014; Lusis, 2000; Wentzel et al., 
2012). Synthesis of LDL-c is up-regulated in both obesity and metabolic syndrome, whilst the 
cardio-protective HDL-c is down-regulated (Tchernof and Després, 2013). 
1.1.3 Non-alcoholic fatty liver disease and diabetes 
Non-alcoholic fatty liver disease (NAFLD) is a multi-stage disease that initially refers to the 
accumulation of hepatic steatosis (abnormal accumulation of lipids in the liver), that then can 
progress to steatohepatitis (abnormal accumulation of fat and inflammation in the liver) and 
eventually fibrosis and cirrhosis (Sattar et al., 2014). Obesity and metabolic syndrome are 
closely linked to incidence of NAFLD due to the established roles of visceral obesity, 
dyslipidaemia and insulin resistance in development of NAFLD (Smith and Adams, 2011; Tilg 
and Moschen, 2010).  
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Visceral adipose tissue increases the synthesis of fatty acids, which are directly transported to 
the liver due to the proximity of visceral adipose tissue to the hepatic portal circulation (Ritchie 
and Connell, 2007). This promotes hepatic insulin resistance, and provides a substrate for 
lipoprotein synthesis and lipid storage in hepatocytes (Maury and Brichard, 2010). Lipid 
storage in hepatocytes (liver cells) impairs the function of the liver, in particular hepatic insulin 
sensitivity, and can lead to the development of fibrosis and inflammation in the liver (Paschos 
and Paletas, 2009). It appears that TNF-α has an important role in the progression of hepatic 
steatosis to steatohepatitis, as significantly higher levels of TNF-α were detected in patients 
with increased fibrosis and inflammation (Crespo et al., 2001). In comparison, adiponectin 
levels were significantly lower in patients with steatohepatitis compared to hepatic steatosis, 
emphasizing the protective role of adiponectin in inhibiting the inflammatory actions of TNF-
α (Kaser et al., 2005). Also, NAFLD is a major risk factor for the development of type 2 
diabetes, and is present in the majority of patients with type 2 diabetes (Tilg and Moschen, 
2010). 
1.2 Current treatment strategies 
While the development of metabolic syndrome involves multiple processes and factors, there 
is a strong case for the importance of obesity in disease risk and progression. Through targeting 
reduction of body weight, especially abdominal fat, it has been observed that there are 
significantly improved markers of health in type 2 diabetes, NAFLD and CVD risk factors 
(Promrat et al., 2010; Wing et al., 2011). Once obesity is established, it becomes increasingly 
difficult to achieve and maintain weight loss due to the psychological and environmental 
barriers that need to be overcome to create lifestyle modifications (Ochner et al., 2015). 
Considering the sheer number of people that are currently obese globally, there is a large 
demand for the development of readily available treatment strategies for successful and 
sustainable weight loss. Currently, bariatric surgery is the most effective method of inducing 
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weight loss. Bariatric surgery involves restricting the size of the stomach and bypassing part of 
the intestine to reduce food absorption (Encinosa et al., 2005). A meta-analysis of 11 studies 
reported that the mean weight loss of patients who underwent bariatric surgery was 26 kg more 
than patients who used non-surgical treatments (Gloy et al., 2013). Whilst bariatric surgery is 
an effective solution for obesity; it is expensive and highly invasive and is thus unsuitable to 
be used as the primary solution to the growing obesity epidemic. 
Standard non-surgical treatment involves lifestyle modifications, including changes to the diet 
and exercise, augmented by the use of prescription weight loss drugs (Brown et al., 2015). 
Current prescription weight loss drugs, such as Orlistat (gastric lipase inhibitor), on average, 
are known to  reduce body weight by only 3 kg, which is an insignificant amount for an obese 
person (Li et al., 2005). Also, some other weight loss drugs have side effects such as 
psychological complications (example – Rimonabant) (Brown et al., 2015). It is hoped that 
functional foods and nutraceuticals may play a role in reducing obesity, although the evidence 
for this is quite weak and is a developing area (Brown et al., 2015). 
1.3 Functional foods 
Functional foods are defined as foods that not only provide nutrition, but also have the capacity 
to treat or prevent diseases (Rahmatullah et al., 2009). It is well documented that natural 
products have been used for thousands of years in traditional medicine (Rahmatullah et al., 
2009). Traditional medicine encompasses a large number of functional foods, although some 
examples that are still commonly used in modern society are green pepper, turmeric and green 
tea (Graziose et al., 2010; Rahmatullah et al., 2009). The possibility for adapting these 
traditional medicines into novel drugs or functional foods has prompted more in-depth studies 
to assess their capacity for the treatment of disease such as obesity. 
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1.4 Spices 
In recent years, a wide range of spices, including ginger, turmeric, black pepper, black 
cardamom, garlic and chilli peppers (capsaicin), have been identified for their potential to treat 
metabolic syndrome (Bhaswant et al., 2015b; Diwan et al., 2013; Kang et al., 2010; 
Rahmatullah et al., 2009; Westerterp-Plantenga et al., 2006). Black cardamom and piperine 
from black pepper have been shown to attenuate effects on diet-induced metabolic syndrome 
in rats (Bhaswant et al., 2015b; Diwan et al., 2013). In these studies, there were significant 
improvements in liver function, blood pressure and blood lipids (Bhaswant et al., 2015b; Diwan 
et al., 2013). Additionally, the therapeutic effect was thought to be mediated through the 
reduction of inflammation and visceral adiposity. Whilst similar studies have not yet been 
conducted in humans, these observations demonstrate the therapeutic potential of spices for the 
treatment of obesity and/or metabolic syndrome. This project will assess the potential of 
curcumin, a bioactive compound from turmeric, as a treatment for diet-induced metabolic 
syndrome. 
1.5 Curcumin 
The commonly used spice turmeric is derived from the rhizomes of the plant Curcuma longa 
(Khalil et al., 2013). Turmeric is a spice that has featured in Indian traditional medicine for 
thousands of years, and in the last few decades, there has been significant research into 
identifying whether components from turmeric are effective in treating chronic diseases 
(Prasad et al., 2014). Curcumin, demethoxycurcumin (DMC) and bisdemethoxycurcumin 
(BDMC), the major active constituents of turmeric, belong to a family of diarylheptanoid 
compounds known as the curcuminoids (Prasad et al., 2014). 
Curcumin, as shown in Figure 1, is a biphenolic compound with hydroxyl groups at the ortho-
position on the two aromatic rings that are connected by a β-diketone bridge containing two 
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double bonds (Begum et al., 2008). The phenolic hydroxyl groups are thought to be critical in 
the antioxidant activity of curcumin, as they may help in scavenging electrons from reactive 
oxygen or nitrogen radicals (Amolins et al., 2009; Priyadarsini et al., 2003). Phenolic 
compounds are constituents of fruits, vegetables and plant-derived beverages including green 
tea, and have been successfully used in trials for the treatment of obesity in previous studies 
(Hsu et al., 2009; Sergent et al., 2012). This further cements the importance of the phenolic 
hydroxyl groups in curcumin. The phenolic hydroxyl groups are conserved across the three 
curcuminoids - curcumin, demethoxycurcumin and bisdemethoxycurcumin (Figure 1). The 
structural difference between the curcuminoids is the presence or absence of methoxy 
substitution on the aromatic ring. Of these three compounds, curcumin is therapeutically the 
most active compound, which suggests that the double methoxy substitution has an important 
role in the various health benefits of curcumin (Prasad et al., 2014). The methoxy groups are 
thought to facilitate the scavenging of free radicals, through their ability to release electrons to 
support the strength of hydrogen bonding from the phenolic hydroxyl groups (Malik and 
Mukherjee, 2014).  
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Figure 1. Curcuminoids structures (Wilken et al., 2011). 
 
Although curcumin has been identified as the most active curcuminoid pharmacologically, 
there has been some argument for increased potency when a combination of all three 
curcuminoids are used (Rates, 2001; Sandur et al., 2007). A mixture of the three curcuminoids, 
with curcumin comprising 77%, had increased anti-inflammatory effects over pure curcumin 
(Sandur et al., 2007). This occurrence could be explained by the removal of possible 
pharmacodynamic synergism or pharmacokinetic influences when a single compound is 
isolated (Rates, 2001). In light of this, this study will use all three curcuminoids together in a 
‘curcuminoid mixture’ that will hence forth be referred to as curcumin. 
1.6 Effects of curcumin 
Using curcumin to attenuate obesity is not a new concept. In fact, the anti-obesity effects of 
curcumin have been explored in a multitude of studies in the last two decades (Prasad et al., 
2014). Studies have shown that curcumin is able to suppress adipogenesis (Ahn et al., 2010), 
as well as being a potent antioxidant (Kirschweng et al., 2015) and anti-inflammatory agent 
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(Maithilikarpagaselvi et al., 2016). The broad spectrum activity of curcumin has been attributed 
to its ability to modulate multiple transcription factors, kinases, cytokines, growth factors and 
other enzymes (Zhou et al., 2011). 
1.6.1 Curcumin targeting adipose tissue 
As mentioned earlier, one of the major mechanisms of obesity is adipose tissue hyperplasia 
(increase in number of adipocytes) which is facilitated by increased adipogenesis. 
Adipogenesis is the process of conversion of preadipocytes into adipocytes. Interestingly, 
many studies  have shown that curcumin is able to suppress the process of adipogenesis (Ahn 
et al., 2010; Ejaz et al., 2009; Ferguson et al., 2016; Kim et al., 2011; Lone et al., 2016), thereby 
suppressing the progression of adipose tissue hyperplasia. It has been reported that weight loss 
by itself is unable to reduce the number of adipocytes, and instead hypertrophy (cell size) is 
decreased (Faust et al., 1978; Ferguson et al., 2016; Jo et al., 2009). Adipocyte number is fairly 
constant in adults, but there is a high turnover rate which is estimated to be 10% per year (Jo 
et al., 2009). Obesity, in developmental years (child and teenager), drastically increases the 
number of adipocytes, which sets the precedent for increased risk of persistent obesity with 
associated complications (Freedman et al., 2001). Since curcumin targets adipogenesis during 
cell turnover, treatment with curcumin is likely to be more effective if it coincides with either 
obesity development in childhood or earlier in the onset of obesity. 
Although the mechanism of adipogenesis suppression is not clear (Ahn et al., 2010; Ejaz et al., 
2009; Ferguson et al., 2016; Kim et al., 2011; Lone et al., 2016), it has been suggested that 
curcumin suppresses adipogenesis through activation of the Wnt/β-catenin signalling pathway 
(Ahn et al., 2010), cell cycle arrest via p27 (Ferguson et al., 2016; Kim et al., 2011), and 
suppression of the transcription factor peroxisome proliferator-activated receptor-γ (PPAR-γ) 
(Ejaz et al., 2009). However, the primary target of curcumin in suppressing adipogenesis 
remains unclear. Studies with 3T3-L1 adipocytes from mice reported a dose-dependent result, 
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whereby treatment with 20μM - 25μM curcumin completely blocked differentiation of 
adipocytes (Ahn et al., 2010; Ferguson et al., 2016). However, this observation was in cell 
lines, and therefore has not yet been translated to animal or human studies. 
A new strategy for encouraging weight loss in recent years has been to promote energy 
expenditure by activating brown adipose tissue (BAT) and converting white adipose tissue 
(WAT) to BAT (Lone et al., 2016). Brown adipose tissue converts energy from food into heat 
through non-shivering thermogenesis, and therefore increases excess energy expenditure. A 
critical protein involved in this process is uncoupling protein 1 (UCP1), and curcumin was 
reported to up-regulate UCP1 at mRNA and protein levels. This occurs in ‘beige’ adipocytes, 
which are WAT that has drastically increased expression of UCP1, suggesting the possibility 
for BAT thermogenic properties (Shabalina et al., 2013). This observation was supported by 
another study that identified the stimulation of UCP1 gene expression to occur with the release 
of norepinephrine (Wang et al., 2015), which is mandatory for the activation of beige 
adipocytes (Cannon and Nedergaard, 2004). This study, conducted with a mouse model (rather 
than cell culture), observed a dose-dependent response (Wang et al., 2015). The greatest up-
regulation of UCP1 mRNA was in response to 100 mg curcumin /kg body weight administered 
by daily oral gavage for 50 days (Wang et al., 2015). These authors concluded that this effect 
was due to increased non-shivering thermogenesis, as it was observed that the curcumin-treated 
mice had increased body temperature compared to controls in response to cold exposure (Wang 
et al., 2015). 
Whilst this study will not examine the changes in adipose tissue at the molecular level (due to 
time restrictions), adipose tissue will be taken and weighed from the various depots to assess 
any alterations in fat mass or location. Weight loss in the visceral fat depots is of particular 
importance due to metabolic abnormalities associated with abdominal adipose tissue. 
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1.6.2 Curcumin targeting chronic inflammation and oxidative stress 
The development of chronic low-grade inflammation in obesity is the outcome of multiple 
factors, including macrophage infiltration, dysregulation of pro-inflammatory cytokines and 
the accumulation of free radicals as outlined in section 1.1. Suppression of adipogenesis by 
curcumin leading to weight loss contributes to a decrease in this chronic inflammation 
(Chuengsamarn et al., 2014). This loss of body fat in mice has been shown to reduce the number 
of adipose-associated macrophages that secrete inflammatory cytokines (Chuengsamarn et al., 
2014). In addition to this, the ability of curcumin to act as an antioxidant and to target both 
adipokines and macrophages has been thoroughly documented (Chuengsamarn et al., 2014; 
Gao et al., 2015; Kirschweng et al., 2015; Maithilikarpagaselvi et al., 2016; Weisberg et al., 
2008). 
Macrophage activation in adipose tissue is responsible for a major portion of the pro-
inflammatory cytokine secretion that is up-regulated in obesity. Therefore, if curcumin is able 
to inhibit this occurrence, it would potentially reduce the amount of chronic inflammation in 
obesity. Macrophage infiltration was blocked after 4 g curcumin /kg of diet was administered 
to high-fat diet-fed mice (Shao et al., 2012). This observation was supported by a similar study 
in mice, where curcumin was given at 3% of the diet (Weisberg et al., 2008). After staining the 
perigonadal WAT with macrophage-specific stains, significantly less macrophage infiltration 
was observed after curcumin supplementation (Shao et al., 2012; Weisberg et al., 2008). This, 
in turn, would reduce the secretion of TNF-α, and subsequently decrease the development of 
insulin resistance and incidence of lipolysis which was demonstrated in these studies (Shao et 
al., 2012; Weisberg et al., 2008). Whilst this has not yet been observed in human studies, the 
fact that it occurred in two separate mouse studies is encouraging. 
The importance of adiponectin in maintaining insulin sensitivity and glucose homeostasis was 
acknowledged in section 1.1. In recent years, the ability of curcumin to elevate the levels of 
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adiponectin has been shown in multiple studies (Chuengsamarn et al., 2014; 
Maithilikarpagaselvi et al., 2016; Panahi et al., 2016). A study in a model of high-fructose diet-
fed rats that were treated with curcumin reported an increase in adiponectin levels that almost 
doubled that of the fructose-fed control group (Maithilikarpagaselvi et al., 2016). This is 
supported by two human trials. A trial of curcumin was conducted in patients with type 2 
diabetes over a six-month period and they reported a steady increase in adiponectin levels in 
response to curcumin treatment (Chuengsamarn et al., 2014). The other clinical trial was 
conducted in patients with metabolic syndrome, where increases in adiponectin levels from 12 
ng/ml to 21 ng/ml were reported (Panahi et al., 2016). In this trial (Panahi et al., 2016), 
curcumin intervention only occurred for a period of eight weeks, whereas there was an increase 
in adiponectin levels that was sustained over another six-month study (Chuengsamarn et al., 
2014). This suggests that a further increase in adiponectin levels was feasible if the period of 
curcumin treatment was extended. 
The antioxidant ability of curcumin was briefly discussed in section 1.3, where it was outlined 
that the phenolic hydroxyl groups allow curcumin to scavenge free radicals. This ability was 
observed in both microsomes and chemical testing that were used to examine whether curcumin 
was able to inhibit lipid peroxidation (Ak and Gülçin, 2008; Priyadarsini et al., 2003). The 
efficiency with which curcumin was able to inhibit lipid peroxidation ranged from 82% to 97% 
(Ak and Gülçin, 2008; Priyadarsini et al., 2003). This antioxidant ability was observed in a 
study in carbon tetrachloride-treated rats, where there was a significant reduction in markers of 
lipid peroxidation compared to the control rats (Naik et al., 2011). The importance of this 
antioxidant ability is that it limits the role that the systemic oxidative stress has in the 
progression of obesity to type 2 diabetes or cardiovascular disease. 
15 
 
1.7 Curcumin bioavailability 
Although the bioactivity of curcumin is well documented, its therapeutic effectiveness is 
limited by its low bioavailability due to poor absorption, rapid metabolism and rapid systemic 
elimination (Khalil et al., 2013). To overcome the problem of low bioavailability, a much 
higher dose (multiple tablets or very large tablets) is required to produce a therapeutic effect in 
humans (Antony et al., 2008; Baum et al., 2007). Whilst curcumin in very high doses of up to 
12 g/day in humans was found to be non-toxic (Anand et al., 2007), this may result in lower 
patient compliance and increased expense (Cheng et al., 2001). For these reasons, recent 
research has focused on improving the bioavailability of curcumin. 
1.8 Nanoparticles 
There have been numerous attempts to increase the bioavailability of curcumin through 
evaluating adjuvants such as piperine (Rinwa and Kumar, 2012), curcumin analogues (Amolins 
et al., 2009) and various nanoformulations (Khalil et al., 2013; Kumari et al., 2010; Liu and 
Chang, 2011). This honours project is part of a larger study that aims to identify whether 
nanoparticles are effective in increasing the bioavailability of curcumin, and thus observe a 
biological response with a lower dose. Nanoparticles have managed to increase the 
bioavailability of curcumin by 55.4 fold compared to curcumin aqueous suspension (Khalil et 
al., 2013). This is shown in Figure 2, which highlights the longer sustained release of curcumin. 
The nanoparticles were developed by decreasing curcumin particles to nanometre size using 
ultrasonification and nanoencapsulating it with poly(lactide-co-glycolide) (PLGA) (Khalil et 
al., 2013). The PLGA functions to prevent premature degradation and improves the solubility 
of curcumin (Khalil et al., 2013). However, PLGA is hydrophobic in nature and has short 
circulation times due to rapid opsonisation and clearance (Khalil et al., 2013). In order to 
overcome the rapid opsonisation, PLGA nanoparticles were coated with polyethylene glycol 
(PEG), making the particles hydrophilic and allowing longer circulation times (Khalil et al., 
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2013). These nanoparticles will be used in dosing curcumin to the rats used in the extension of 
this study. 
 
Figure 2. Comparison of vivo plasma concentrations vs. time profiles of the different 
curcumin formulations (Khalil et al., 2013) 
 
1.9 Project outline 
It is evident that curcumin has considerable potential for the treatment of obesity, providing 
the limitation of poor bioavailability can be overcome. The focus of this study is to determine 
whether curcumin in aqueous solution that is administered to rats with diet-induced metabolic 
syndrome, is able to reverse the pathological symptoms that are associated with obesity. The 
Functional Foods Research Group at the University of Southern Queensland has developed a 
rat model of obesity that allows the testing of functional foods (Panchal et al., 2011; Panchal 
and Brown, 2011). The pathological changes that are associated with obesity have been 
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mimicked in various studies, by feeding rats a high-carbohydrate, high-fat (HCHF) diet 
(Panchal et al., 2011). Control rats fed a corn starch (CS) diet have a lean body type and 
consistently showed no symptoms of metabolic syndrome. Using this animal model of diet-
induced metabolic syndrome, functional foods such as Queen Garnet plum, purple carrots, 
coffee extract, spices such as piperine and cardamom, olive leaf extract and seaweeds have 
been successfully shown to exert positive health benefits in the treatment of metabolic diseases 
(Bhaswant et al., 2015a; Bhaswant et al., 2015b; Diwan et al., 2013; Kumar et al., 2015a; 
Kumar et al., 2015b; Panchal et al., 2012; Poudyal et al., 2010). 
This project will be conducted over a 16-week period using this rat model of obesity. During 
the first 8 weeks, three groups of male Wistar rats will be fed the HCHF diet and another three 
groups will be fed the CS diet. The HCHF diet, during these 8 weeks, will induce an obese 
phenotype. After 8 weeks, the treatment phase will commence where, within each of the diet 
categories, one group will be given no curcumin (control), a second group will be given 5 
mg/kg body weight/day curcumin, and a third group will be given 100 mg/kg body weight/day 
curcumin through oral gavage of aqueous suspension. 
In order to assess the effectiveness of curcumin in attenuating obesity, various physiological 
measurements will be undertaken at 0 week, 8 weeks and 16 weeks. The differences in fat 
deposition will be traced between treatment groups through assessment of body composition 
at 8 and 16 weeks (Dual-energy X-ray Absorptiometry), and then adipose tissues will be 
extracted and weighed at termination of the project. An oral glucose tolerance test will be 
performed to identify the sensitivity of rats to glucose. Cardiovascular health will be monitored 
throughout the 16 weeks through systolic blood pressure measurements and Langendorff heart 
preparation will be used to assess diastolic stiffness. Heart and liver samples will be prepared 
for histopathological analysis to assess the level of tissue inflammation and possible fat 
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deposition. Blood samples will be collected from rats during terminal experiments to identify 
metabolic parameters such as blood lipids concentrations. 
Evaluation of curcumin as a potential agent to reduce the effects of diet-induced obesity in rats 
has been conducted numerous times before (Table 2). However, previous studies have focused 
primarily on analysing one or two components of metabolic syndrome whereas my project 
covers a much broader area. In addition, the impact of curcumin on cardiovascular health is an 
area that has not been explored in a model of diet-induced obesity. The cause and effect 
relationships in the development of the numerous conditions that characterise metabolic 
syndrome are poorly understood. Therefore, it is desirable to explore curcumin’s effect on a 
number of symptoms of metabolic syndrome. 
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Table 2. Similarities and differences between my study and previous studies which have assessed the potential of curcumin to reduce 
the effects of diet-induced obesity
 Diet-
induced 
obesity? 
Curcumin 
dose 
Oral glucose 
tolerance test 
Blood 
pressure 
Cardiovascular 
health 
Body 
composition 
Plasma 
tests 
Tissue 
inflammation 
Observed 
improvement 
My project Y 5mg/kg/day 
100mg/kg/day 
Y Y Y Y Y Y - 
(Shao et al., 2012) Y 4g/kg diet Y N N Y – MRI scan Y – lipid 
N – liver 
N Glucose tolerance 
Body weight 
Liver health 
(Maithilikarpagaselvi 
et al., 2016) 
Y 200mg/kg/day Y N N N Y – lipid 
N – liver 
N Glucose tolerance 
Body weight 
Plasma lipid 
(Ding et al., 2016) Y 80mg/kg/day 
40mg/kg/day 
Y N N Y Y – lipid 
N – liver 
Y – adipose 
and liver 
Glucose tolerance 
Body weight 
Plasma lipid 
Liver health 
(Um et al., 2013) Y 0.15% diet Y N N N Y – lipid 
Y – liver 
N Glucose tolerance 
Body weight 
Plasma lipid 
Liver health 
(Correa et al., 2013) N – renal 
failure 
120mg/kg/day N Y Y N N N Blood pressure 
Cardiovascular 
Abbreviations used: Y, tested; N, not tested 
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1.10 Significance and objectives 
Curcumin, through turmeric, has been a component of human diets for a long time. Previous 
research has identified the effects of curcumin in improving various health aspects as outlined 
in earlier sections. Due to low bioavailability, most of the health benefits have not been 
translated to humans.  
My project will contribute to the general understanding of the role of curcumin in attenuating 
diet-induced obesity, and more specifically, it will assess the effects of curcumin on 
cardiovascular structure and function, liver structure and metabolic functions. Additionally, 
the results of my project will be compared with a sister-study involving nanoparticles in the 
delivery of curcumin. 
The objectives for this project are to determine the effectiveness of low (5 mg/kg/day) and 
high (100 mg/kg/day) doses of curcumin in attenuating: 
  Symptoms of diet-induced obesity including body weight gain, in particular the 
distribution and composition of body weight, tissue inflammation and abnormal fat 
deposition 
 Cardiovascular structure and function complications associated with metabolic 
syndrome 
 Liver structure changes associated with metabolic syndrome and NAFLD 
 Metabolic complications associated with metabolic syndrome including glucose 
intolerance, dyslipidaemia and metabolic rate 
Additionally, my project will act as a comparison point for the study of nanoparticles 
containing curcumin. 
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1.11 Hypothesis 
I hypothesise that   
 The low dose of curcumin (5 mg/kg/day) orally will have no effects on any of the 
parameters in obese rats 
 The high dose of curcumin (100 mg/kg/day) orally will attenuate diet-induced obesity, 
changes in heart and liver structure and function, and metabolic changes induced by a 
HCHF diet 
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Chapter 2. Materials and Methods 
 
2.1 Materials 
Curcumin for this project was obtained from Acros Organics (New Jersey, USA), and was a 
mixture of curcumin, demothoxycurumin and bisdemethoxycurcumin, at a purity greater than 
98%. Beef tallow was purchased from Carey Brothers, Warwick, QLD, Australia. Condensed 
milk was purchased from Coles Kearney Springs, Toowoomba, QLD, Australia. Meat-free 
powdered rat food was purchased from Speciality Feeds, Glen Forrest, WA, Australia. Hubble, 
Mendel and Wakeman salt mixture was purchased from MP Biomedicals, Seven Hills, NSW, 
Australia. Fructose was purchased from Tate & Lyle, Wacol, QLD, Australia. Corn starch was 
purchased from Agri Food Ingredients, Kew East, VIC, Australia. All laboratory chemicals 
were purchased from Sigma-Aldrich Australia, Castle Hill, NSW, Australia, unless otherwise 
specified at their first appearance in the text. 
2.2 Rats, experimental groups and housing 
All experimental protocols were approved by the Animal Ethics Committee of the University 
of Southern Queensland (Project number – 15REA008) under the guidelines of the National 
Health and Medical Research Council of Australia. In this project, 72 male Wistar rats (8-9 
weeks old, 335-340 g) were sourced from the Animal Resource Centre, Perth, WA, Australia. 
These rats were 7 weeks old when they arrived and were given approximately one week to 
acclimatise. During the acclimatisation, rats were fed standard laboratory chow diet. Rats were 
then randomly distributed into six experimental groups with each containing 12 rats.  
1. C – rats received corn starch (CS) diet for 16 weeks 
2. CC5 – rats received CS diet for 16 weeks, and were given curcumin 5 mg/kg/day as 
oral gavage from week 8 to 16 of protocol  
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3. CC100 - rats received CS diet for 16 weeks, and were given curcumin 100 mg/kg/day 
as oral gavage from week 8 to 16 of protocol  
4. H – rats received high-carbohydrate, high-fat (HCHF) diet for 16 weeks 
5. HC5 - rats received HCHF diet for 16 weeks, and were given curcumin 5 mg/kg/day 
as oral gavage from week 8 to 16 of protocol 
6. HC100 - rats received HCHF diet for 16 weeks, and were given curcumin 100 
mg/kg/day as oral gavage from week 8 to 16 of protocol 
This experimental protocol is outlined in Figure 3. All rats were housed in a temperature-
controlled (21 ± 2ºC) room with an automated 12-hour light and dark cycle. All rats were 
housed in individual cages in the animal house at the University of Southern Queensland, 
Toowoomba campus and had ad libitum access to food and water. 
Figure 3. Timeline of the 16 week protocol. 
 
 CS, corn starch diet; HCHF, high-carbohydrate, high-fat diet; OGTT, oral glucose tolerance 
test; SBP, systolic blood pressure; DXA, Dual-energy X-ray Absorptiometry  
OGTT 
OGTT 
SBP 
DXA 
Oxymax 
Langendorff 
Tissue histology 
Biochemical analysis 
 
CS or HCHF diet 
0 week 8 week 16 week 
Treatment period 
OGTT OGTT 
SBP 
DXA 
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2.3 Diets 
The CS diet contained 570 g of corn starch, 155 g of powdered rat food, 25 g of Hubble, Mendel 
and Wakeman salt mixture, and 250 mL of water per kilogram of diet. The HCHF diet consisted 
of 175 g of fructose, 395 g of sweetened condensed milk, 200 g of beef tallow, 155 g of 
powdered rat food, 25 g of Hubble, Mendel and Wakeman salt mixture, and 50 mL of water 
per kilogram of diet. In addition, the drinking water for the HCHF group was supplemented 
with 25% fructose. The energy intake for each diet was calculated from the following values 
in kilojoules per gram; fructose, 15.40; CS, 15.94; condensed milk, 13.80; beef tallow, 37.70; 
and powdered rat food, 13.80. The energy densities of the CS and HCHF diets were 11.23 kJ/g 
and 17.83 kJ/g of food, respectively, and an additional 3.65 kJ/mL in the drinking water for the 
HCHF diet-fed rats. 
2.4 Daily measurements 
The body weight and intake of food and water for individual rats were measured every day. 
The daily energy intake was then calculated using the known energy densities of the CS and 
HCHF diets.  
CS daily energy intake (kJ) = 11.23 × daily food intake (g) 
HCHF daily energy intake (kJ) = (17.83 × daily food intake (g)) 
                                                            +(3.65 × daily water intake (ml)) 
The feed conversion efficiency was calculated using the following formula (Panchal et al., 
2011).  
Feed conversion efficiency =  
mean body weight gain (g)
daily energy intake (kJ)
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2.5 Curcumin intervention 
Rats were treated with either 5 mg/kg/day or 100 mg/kg/day of curcumin. These doses of 
curcumin were given as an oral gavage of curcumin aqueous suspension. In order to generate 
a homogenous suspension of curcumin, the aqueous mixture of curcumin was vortexed at 
maximum speed for approximately 20 seconds, prior to uptake in the syringe for each rat. A 1 
mL syringe with an 18 gauge plastic gavage needle was used to gavage curcumin suspension 
orally to rats. 
2.6 Body composition measurement 
The body composition of rats were measured at 8 and 16 weeks under light anaesthesia using 
Zoletil (tiletamine 10 mg/kg, zolazepam 10 mg/kg; Virbac, Peakhurst, NSW, Australia) 
intraperitoneally. Prior to sedation, the procedure room was heated to 25°C. Body composition 
was measured using a Norland XR-46 Dual-energy X-ray Absorptiometry (DXA) densitometer 
(Norland Corp., Fort Atkinson, WI, USA) and data analysed using the manufacturer’s 
recommended software for use in laboratory animals (Small Subject Analysis Software, 
version 2.5.3/1.3.1; Norland Corp.). 
2.7 Systolic blood pressure measurement 
The systolic blood pressure (SBP) of rats were measured at 8 and 16 weeks under light 
anaesthesia using Zoletil (tiletamine 10 mg/kg, zolazepam 10 mg/kg; Virbac, Peakhurst, NSW, 
Australia) intraperitoneally. Prior to sedation, the procedure room was heated to 25°C. Blood 
pressure measurement was performed using an NIBP Controller, model number INI25/R 
(ADInstruments, Bella Vista, NSW, Australia), connected to a PowerLab data acquisition unit 
(ADInstruments). The machine was calibrated and then the MLT125/R tail cuff 
(ADInstruments) was slipped over the tail of the sedated rat and the MLT125/R pulse 
transducer (ADInstruments) placed just posterior to the cuff on the tail. Occlusion was initiated 
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and blood pressure readings taken once a stable pulse was detected on LabChart Pro 
(ADInstruments). Five to six SBP readings were taken for each rat, and then the average for 
each rat was used to calculate the group’s average. After the blood pressure measurements, 
abdominal circumference was measured at both 8 and 16 weeks whilst the rats were under light 
anaesthesia. A standard measuring tape was used to measure the circumference of the abdomen 
in the ventral recumbent position (Panchal et al., 2011). 
2.8 Oral glucose tolerance test 
An oral glucose tolerance test (OGTT) was performed at 0, 8 and 16 weeks. The rats were 
starved 12 hours prior to testing during which time fructose-supplemented water was replaced 
with tap water. Overnight fasting blood glucose concentration was determined in tail vein blood 
using a glucose strip (Freestyle Optium Blood Glucose Test Strips, Abbott Diabetes Care Ltd., 
Witney, Oxon, UK) attached to a Medisense Precision Q.I.D glucometer (Abbott Laboratories, 
Bedford, MA). After recording this initial 0 minute blood glucose concentration, all rats were 
given 40% aqueous glucose solution (2 g glucose/kg body weight) via oral gavage using a 5 
mL syringe and an 18 gauge plastic gavage needle. Tail vein blood samples were taken at 30, 
60, 90 and 120 minutes following glucose administration (Panchal et al., 2011). After the final 
reading was taken, group-specific diets and water were given to the rats. The area under the 
curve (AUC) was calculated from the graph showing blood glucose concentrations against 
time. 
2.9 Calorimetry 
Indirect calorimetry was performed using the Oxymax system (Columbus Instruments, 
Columbus, USA). The initial body weight, weight of the bowl of food and water bottle was 
recorded. Rats were placed into metabolic cages calibrated using special purpose gas consisting 
of 20.8% O2, 0.5% CO2 and remaining N2. Metabolic readings were taken for 14 hours, 
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including a 12 hour dark cycle. The final body weight, and weight of food and water bowls 
were then recorded. Respiratory exchange ratio (RER), heat and energy expenditure were 
calculated according to the manufacturer’s instructions. 
2.10 Terminal euthanasia and Langendorff heart preparation 
Intraperitoneal injection of Lethabarb (pentobarbitone sodium, 100 mg/kg, Virbac) was used 
to induce terminal euthanasia. Immediately following euthanasia, heparin (200 IU) was 
injected into the right femoral vein to allow collection of ~6 mL of blood from the abdominal 
aorta after opening the abdomen. The blood was immediately collected into heparinised tubes 
and centrifuged at 5000 × g for 15 minutes to obtain plasma, which was then stored in five 
microcentrifuge tubes (for each rat) at –20°C before analysis. The heart was removed for 
isolated Langendorff heart preparation. Hearts isolated from euthanised rats were perfused with 
modified Krebs–Henseleit bicarbonate buffer, containing (in mmol/L): NaCl, 119.1; KCl, 4.75; 
MgSO4, 1.19; KH2PO4, 1.19; NaHCO3, 25.0; glucose, 11.0; and CaCl2, 2.16. Buffer was 
bubbled with 95% O2–5% CO2 and maintained at 35°C. Isovolumetric ventricular function was 
measured by inserting a latex balloon catheter into the left ventricle connected to a Capto SP844 
MLT844 physiological pressure transducer and Chart software on a Maclab system 
(ADInstruments). All left ventricular end-diastolic pressure values were measured during 
pacing of the heart at 250 beats/minute using an electrical stimulator. End-diastolic pressures 
were obtained from 0 to 30 mmHg for calculation of diastolic stiffness constant (κ, 
dimensionless) (Panchal et al., 2011). 
2.11 Organ weights 
The liver, abdominal fat (retroperitoneal, omental and epididymal), spleen, brown fat and 
kidneys were removed and weighed. After the isolated Langendorff heart preparation was 
completed, the heart was cut so that the right ventricle was separated from the left ventricle and 
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septum and the two parts of the heart were weighed separately. These organ weights were 
normalised relative to the tibial length at the time of their removal (in mg of tissue/mm of tibial 
length) (Panchal et al., 2011). The visceral adiposity index (VAI) was then calculated using 
this formula; 
VAI (%) =
retroperitoneal fat (g) + omental fat (g) + epididymal fat (g)
body weight (g)
 × 100 
2.12 Histology 
The liver, heart, kidney and small and large intestines from four rats in each group were isolated 
and then fixed in 10% neutral buffered formalin. This was performed approximately 5-7 
minutes after euthanasia. Two slides were prepared per tissue specimen and two random, non-
overlapping fields per slide were taken to avoid biased analysis. 3 days after fixing, the samples 
were processed and embedded in paraffin wax. Thin sections (5 μm) of the samples were cut 
and stained with haematoxylin and eosin stain for determination of inflammatory cell 
infiltration (20×) and liver fat vacuole presence (20×). EVOS FLC microscope (Tokyo, Japan) 
was used to capture images of these slides. 
2.13 Biochemical analysis 
The plasma samples collected during the terminal experiments were used to test for plasma 
concentrations of biochemical markers. Plasma concentrations of total cholesterol and 
triglycerides were determined using kits and controls supplied by Olympus (Japan, Tokyo) and 
an AU 400 Olympus analyser (Panchal et al., 2011). Non-esterified fatty acids (NEFA) were 
determined using a commercial kit (Wako Diagnostics, Osaka, Japan) (Panchal et al., 2011). 
2.14 Statistical analysis 
All data are presented as mean ± standard error of the mean (SEM). Any variance within the 
data was detected using Bartlett’s test and variables that are not normally distributed were 
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transformed using log10 function prior to statistical analysis. Data from C, CC5, CC100, H, 
HC5 and HC100 groups were tested by two-way analysis of variance for the effects of diet, 
curcumin and their interaction. When the interactions and/or main effects were significant, 
means were compared using the Newman-Keuls multiple comparison post hoc test. A P value 
of <0.05 was considered as statistically significant. All statistical analyses were performed 
using Prism version 5.00 for Windows (GraphPad Software, San Diego, CA, USA). 
Chapter 3. Results 
 
3.1 Physiological variables 
Table 3 displays values for body weight, daily intake of food, water and energy and overall 
feed efficiency for all groups of rats at week 8 (pre-treatment) and week16 (post-treatment).  
Initial body weights of all groups were very similar (P = 0.23), but after 16 weeks, the HCHF 
diet groups had significantly higher body weights than the CS diet groups (P < 0.001). 
Curcumin treatment at 5 and 100 mg/kg/day in both the HCHF (HC5 and HC100) and CS (CC5 
and CC100) diet groups did not change body weight compared to controls at 16 weeks. Weekly 
body weights across the 16-week period for the three HCHF diet groups (H, HC5 and HC100) 
(Figure 4A) did not differ at any time, and neither did the body weights of the three groups on 
CS diet (C, CC5 and CC100). In comparison, for the majority of this 16-week period, the body 
weights of the HCHF diet groups were significantly higher than those of the CS diet groups 
(P<0.0001). In other words, body weight gain at week 16, as a percentage of body weight at 8 
weeks (Figure 4B), was significantly higher for the HCHF diet groups compared with the CS 
diet groups (P<0.0001), while having no difference with the curcumin intervention at both 5 
and 100 mg/kg/day doses. 
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Water intake during the pre-treatment 0-8 week period (Table 3) for the three groups on HCHF 
diet (H, HC5 and HC100) was significantly lower than that for the three groups on CS diet (C, 
CC5 and CC100) (P<0.001). In comparison, water intake during the treatment period (8-16 
week) did not differ between the HCHF and CS diet groups. This change in water intake 
occurred due to the increase in water intake of the HCHF diet groups during the treatment 
period compared to the pre-treatment period. Food intake during the pre-treatment period (0-8 
week) for the three groups on CS diet was higher than that for the HCHF diet groups 
(P<0.0001). This difference in food intake continued during the treatment period (8-16 week), 
where the food intake of the three CS diet groups was higher than those of the HCHF diet 
groups (P<0.0001).  
Although the food intake was lower for HCHF diet groups compared to CS diet groups, energy 
intake during the pre-treatment period (0-8 week) and post-treatment period (8-16 week) for 
the three HCHF diet groups was higher than those for the three CS diet groups (P<0.0001). 
This increased energy intake was due to the higher energy density of HCHF diet (17.83 kJ/g) 
compared to CS diet (11.23 kJ/g). During the pre-treatment period, HC5 and HC100 had lower 
energy intake compared to H rats while no difference was observed in energy intake within the 
CS diet groups. The difference in energy intake between H and HC100 rats was sustained 
during the treatment period while H and HC5 rats had no difference in energy intake during 
this period. Curcumin treatment did not change energy intake in CC5 and CC100 compared to 
C rats. Feed conversion efficiency during the pre-treatment period (0-8 week) for the three 
groups on HCHF diet was higher than that for the CS diet groups (P<0.0001), and this remained 
the same during the post-treatment period (8-16 weeks). During the pre-treatment period, feed 
conversion efficiency for the CC5 and CC100 curcumin groups was significantly lower than 
that for the C control group (p<0.05). Curcumin treatment from 8-16 weeks did not introduce 
any changes in the feed efficiency in either diet groups (Table 3).
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Table 3: Body weight and daily intake of food, water and energy and overall feed efficiency 
Variable C CC5 CC100 H HC5 HC100 
P Value 
Diet Treatment Interaction 
Initial body weight (g) 337 ± 1 337 ± 1 338 ± 1 339 ± 1 339 ± 1 337 ± 1 0.2250 0.8468 0.2306 
Final body weight (g) 394 ± 7b 386 ± 9b 385 ± 9b 510 ± 14a 495 ± 10a 498 ± 10a < 0.0001 0.3766 0.9275 
Water intake (0-8 
weeks), mL/day 
33.6 ± 4.34a 25.3 ± 1.44bc 28.8 ± 3.20ab 22.0 ± 1.41bc 24.3 ± 1.23bc 20.2 ± 1.11c 0.0004 0.2984 0.0712 
Water intake (8-16 
weeks), mL/day 
32.6 ± 3.92 24.9 ± 1.37 25.6 ± 1.64 29.1 ± 1.42 32.0 ± 2.05 26.6 ± 1.26 0.4777 0.1185 0.0186 
Food intake (0-8 weeks), 
mL/day 
42.6 ± 1.99a 40.2 ± 1.34a 40.7 ± 1.39a 26.8 ± 0.760b 22.7 ± 0.609b 23.1 ± 0.378b < 0.0001 0.0220 0.7649 
Food intake (8-16 
weeks), mL/day 
40.4 ± 1.29a 38.7 ± 1.70a 39.3  ± 1.59a 27.9 ± 1.29b 25.2 ± 0.779b 24.3 ± 0.760b < 0.0001 0.1493 0.6399 
Energy intake (0-8 
weeks), kJ/day  
477 ± 20.8b 451 ± 15.1b 458 ± 15.1b 550 ± 18.1a 498 ± 9.42b 500 ± 7.91b < 0.0001 0.0163 0.5140 
Energy intake (8-16 
weeks), kJ/day 
452 ± 12.0c 436 ± 17.2c 431 ± 15.9c 596 ± 23.4a 566 ± 13.3ab 531 ± 15.2b < 0.0001 0.0452 0.4206 
Food conversion 
efficiency (0-8 weeks), 
g/kJ 
0.075 ± 0.015b 0.040 ± 0.008c 0.023 ± 0.013c 0.160 ± 0.014a 0.143 ± 0.008a 0.158 ± 0.008a < 0.0001 0.0272 0.0809 
Food conversion 
efficiency (8-16 weeks), 
g/kJ 
0.072 ± 0.011b 0.072 ± 0.013b 0.081 ± 0.008b 0.154 ± 0.012a 0.154 ± 0.010a 0.151 ± 0.011a < 0.0001 0.9531 0.8256 
Values are mean ± SEM, n = 8–12. Means in a row with unlike superscripts differ, P < 0.05. 
C, corn starch diet-fed rats; CC5, corn starch diet-fed rats supplemented with 5 mg/kg/day curcumin; CC100, corn starch diet-fed rats 
supplemented with 100 mg/kg/day curcumin; H, high-carbohydrate, high-fat diet fed rats; HC5, high-carbohydrate, high-fat diet fed rats 
supplemented with 5 mg/kg/day curcumin; HC100, high-carbohydrate, high-fat diet fed rats supplemented with 100 mg/kg/day curcumin. 
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Figure 4. Effects of curcumin on body weight (A) and body weight gain from 8-16 weeks as a percentage of body weight at 8 weeks 
(B).  
Values are mean ± SEM, n = 8–12. Means without a common letter differ, P < 0.05.  
C, corn starch diet-fed rats; CC5, corn starch diet-fed rats supplemented with 5 mg/kg/day curcumin; CC100, corn starch diet-fed rats 
supplemented with 100 mg/kg/day curcumin; H, high-carbohydrate, high-fat diet fed rats; HC5, high-carbohydrate, high-fat diet fed rats 
supplemented with 5 mg/kg/day curcumin; HC100, high-carbohydrate, high-fat diet-fed rats supplemented with 100 mg/kg/day curcumin
 P Value 
Figure Diet Treatment Interaction 
A < 0.0001 0.3766 0.9275 
B < 0.0001 0.6812 0.3859 
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3.2 Body composition 
Table 4 displays data for body composition, at the end of the pre-treatment period at 8 weeks 
and at the end of the treatment period at 16 weeks, for all groups of rats. At both 8 and 16 
weeks, the bone mineral content (BMC) for the three HCHF diet groups was higher than those 
for the three CS diet groups (P < 0.001). Figure 5A displays the change in bone mineral content 
(BMC) between 8 and 16 weeks. Within the HCHF diet groups, the change in BMC for the 
HC100 rats was significantly higher than that for the H rats (P < 0.05), and while the change 
in BMC for the HC5 rats was also higher than that for the H rats, the difference was not 
significant. In comparison, differences in BMC within the three CS diet groups were not 
significant. The bone mineral density (BMD) did not differ between all six groups of rats at 
both 8 and 16 weeks. 
Total fat mass at 8 weeks (Table 4) for the three HCHF diet groups was significantly higher 
than those for the three CS diet groups (P<0.0001). While there were no significant differences 
in total fat mass between the HCHF diet groups, the total fat mass at 8 weeks for the CC5 and 
CC100 groups were significantly lower than that for the C group (P<0.05). At 16 weeks, the 
total fat mass for the three HCHF diet groups was again higher than those for the three CS diet 
groups (P<0.0001), and curcumin intervention at both 5 and 100 mg/kg/day did not change 
total fat mass in rats (Table 4). The change in total fat mass between 8 and 16 weeks for the 
three HCHF diet groups (Figure 5B) was also greater than those for the three CS diet groups 
(P<0.0001). The change in total fat mass between 8 and 16 weeks was not different within the 
HCHF and CS diet groups. 
In contrast to total fat mass, total lean mass for the HCHF and CS diet groups were not different, 
and likewise, differences between groups within each diet category were not significant (Table 
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4). Similarly, changes in lean mass between 8 and 16 weeks (Figure 5C) were not significantly 
different, both between and within dietary categories. 
As with total fat mass, the abdominal circumference at both 8 weeks and 16 weeks for the three 
groups on HCHF diet was significantly higher than those for the three CS diet groups 
(P<0.0001). Differences between groups within each diet category were not significant (Table 
4). 
Visceral adiposity at 16 weeks for the HCHF diet groups was also significantly higher than 
those for the CS diet groups (P<0.0001). While visceral adiposity in both dietary categories for 
the curcumin groups were lower than the corresponding control, only that for the HC100 group 
was significantly lower than its H control group (P<0.05). 
Values for tissue weights at 16 weeks, expressed in mg/mm tibial length, were also compared 
between and within dietary categories (Table 4). Retroperitoneal fat for the three groups on 
HCHF diet was significantly higher than those for the three groups on CS diet (P<0.0001). 
Also, retroperitoneal fat for the HC5 and HC100 rats were significantly lower than that for the 
H rats (p<0.05). Epididymal, omental and total abdominal fat for the three HCHF diet groups 
were all significantly higher than those for the three CS diet groups (p<0.0001), and on no 
occasions were differences between groups within each dietary category significant (Table 4). 
Differences in dorsal brown fat between and within dietary categories were not significant 
(Table 4).
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Table 4: Body composition at 8 and 16 weeks. 
 
Values are mean ± SEM, n = 12. Means in a row with superscripts without a common letter differ, P < 0.05. C, corn starch diet-fed rats; CC5, 
corn starch diet-fed rats supplemented with 5 mg/kg/day curcumin; CC100, corn starch diet-fed rats supplemented with 100 mg/kg/day 
curcumin; H, high-carbohydrate, high-fat diet fed rats; HC5, high-carbohydrate, high-fat diet fed rats supplemented with 5 mg/kg/day curcumin; 
HC100, high-carbohydrate, high-fat diet fed rats supplemented with 100 mg/kg/day. 
Variable C CC5 CC100 H HC5 HC100 P Value 
       Diet Treatment Interaction 
Bone mineral content (8 
weeks), g  
11.7 ± 0.419bc 10.7 ± 0.210c 10.5 ± 0.226c 13.4 ± 0.584a 12.8 ± 0.337ab 12.8 ± 0.392ab < 0.0001 0.0430 0.7288 
Bone mineral content (16 
weeks), g  
12.9 ± 0.359b 12.0 ± 0.382b 11.6 ± 0.349b 15.9 ± 0.528a 16.2 ± 0.588a 16.9 ± 0.564a < 0.0001 0.8150 0.0774 
Bone mineral density (8 
weeks), g/cm2 
0.174 ± 0.00179 0.174 ± 0.00319 0.170 ± 0.00237 0.178 ± 0.00313 0.174 ± 0.00273 0.172 ± 0.00280 0.3614 0.1764 0.7553 
Bone mineral density (16 
weeks), g/cm2 
0.181 ± 0.00209 0.181 ± 0.00170 0.178 ± 0.00398 0.190 ± 0.00407 0.188 ± 0.00282 0.185 ± 0.00364 0.0190 0.8248 0.6393 
Total fat mass at 8 weeks, g 85 ± 9.51b 57 ± 3.82c 55 ± 4.16c 131 ± 15.8a 123 ± 7.31a 131 ± 9.40a < 0.0001 0.0926 0.2199 
Total fat mass at 16 weeks, g 85 ± 6.66b 70 ± 6.60b 66 ± 5.68b 178 ± 11.1a 185 ± 13.8a 202 ± 12.8a < 0.0001 0.7494 0.1676 
Total lean mass at 8 weeks, g 262 ± 5.02 277 ± 4.52 275 ± 4.86 287 ± 9.43 272 ± 4.68 274 ± 7.76 0.1801 0.9835 0.0279 
Total lean mass at 16 weeks, g 295 ± 5.31 292 ± 7.42 292 ± 7.42 315 ± 8.79 289 ± 5.87 291 ± 6.99 0.2735 0.0568 0.2486 
Abdominal circumference at 8 
weeks, cm 
18.9 ± 0.1b 18.9 ± 0.1b 18.4 ± 0.2b 20.3 ± 0.2a 20.1 ± 0.2a 20.4 ± 0.1a < 0.0001 0.5336 0.0735 
Abdominal circumference at 
16 weeks, cm 
19.3 ± 0.1b 19.4 ± 0.2b 18.4 ± 0.1c 22.1 ± 0.3a 22.0 ± 0.3a 22.1 ± 0.3a < 0.0001 0.1467 0.0891 
Visceral adiposity % at 16 
weeks 
5.52 ± 0.26c 5.36 ± 0.29c 5.16 ± 0.22c 8.94 ± 0.27a 8.37 ± 0.34ab 7.97 ± 0.29b < 0.0001 0.0673 0.5440 
Tissue wet weight, mg/mm 
tibial length, at 16 weeks 
         
Retroperitoneal 242 ± 12.7c 194 ± 7.77c 211 ± 10.4c 501 ± 21.6a 414 ± 27.9b 436 ± 22.0b < 0.0001 0.0013 0.5070 
Epididymal  76 ± 8.05b 72 ± 5.21b 68 ± 7.96b 178 ± 12.3a 161 ± 17.3a 143 ± 12.5a < 0.0001 0.1576 0.4763 
Omental 137 ± 10.1b 126 ± 7.28b 123 ± 6.73b 249 ± 14.6a 226 ± 11.9a 219 ± 10.9a < 0.0001 0.1088 0.7421 
Total abdominal fat 455 ± 25.0c 423 ± 33.7c 402 ± 22.8c 927 ± 35.1a 801 ± 49.1b 797 ± 39.1b < 0.0001 0.0071 0.4620 
Dorsal brown fat  32.5 ± 1.93 27.9 ± 2.15 29.9 ± 2.67 33.1 ± 1.83 29.4 ± 1.34 30.7 ± 1.54 0.5638 0.1320 0.9735 
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Figure 5. Effects of curcumin on changes in bone mineral content from 8 – 16 weeks (A), changes in fat mass from 8 – 16 weeks (B) 
and changes in lean mass from 8 – 16 weeks (C). 
Values are mean ± SEM, n = 8-12. Means without a common letter differ, P < 0.05. C, corn starch diet-fed rats; CC5, corn starch diet-fed rats 
supplemented with 5 mg/kg/day curcumin; CC100, corn starch diet-fed rats supplemented with 100 mg/kg/day curcumin; H, high-carbohydrate, 
high-fat diet fed rats; HC5, high-carbohydrate, high-fat diet fed rats supplemented with 5 mg/kg/day curcumin; HC100, high-carbohydrate, 
high-fat diet-fed rats supplemented with 100 mg/kg/day curcumin.
 P Value 
Figure Diet Treatment Interaction 
A < 0.0001 0.1625 0.1337 
B < 0.0001 0.4337 0.4422 
C 0.7062 0.0616 0.4739 
A B 
C 
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3.3 Metabolic variables 
The effects of curcumin on overnight fasting glucose concentration and sensitivity to a glucose 
load were tested through OGTT and displayed in Figure 6A as the area under the curve (AUC). 
The AUC for the HCHF diet groups was significantly higher than that for CC5 and CC100 
groups (P < 0.0001), but not the C group. While the AUC for HC5 and HC100 groups was 
slightly lower than the H group, this was not significantly different. In comparison, the AUC 
for both CC5 and CC100 groups was lower than the C group (P < 0.01).  
The effects of curcumin on respiratory exchange ratio (RER) was calculated through 
calorimetry testing, and is displayed in Figure 6B. The RER for CS diet groups was 
significantly higher than for HCHF diet groups (P < 0.0001), and there was no difference 
between treatment and control groups. 
The effects of curcumin on plasma total cholesterol, triglyceride and NEFA concentrations are 
displayed in Figure 7. There was no difference in plasma concentrations of total cholesterol 
between all diet and treatment groups (Figure 7A). However, there was a clear diet impact on 
plasma concentrations of triglycerides (Figure 7B) and NEFA (Figure 7C), where HCHF diet 
groups were higher than the CS diet groups (P < 0.0001). In comparison, curcumin intervention 
had no effect at both 5 mg/kg/day and 100 mg/kg/day on plasma concentrations of triglycerides 
and NEFA. 
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Figure 6. Effects of curcumin on oral glucose tolerance at 16 weeks (A) and 
respiratory exchange ratio at 16 weeks (B). 
Values are mean ± SEM, n = 8-12. Means without a common letter differ, P < 0.05. C, corn 
starch diet-fed rats; CC5, corn starch diet-fed rats supplemented with 5 mg/kg/day curcumin; 
CC100, corn starch diet-fed rats supplemented with 100 mg/kg/day curcumin; H, high-
carbohydrate, high-fat diet fed rats; HC5, high-carbohydrate, high-fat diet fed rats 
supplemented with 5 mg/kg/day curcumin; HC100, high-carbohydrate, high-fat diet-fed rats 
supplemented with 100 mg/kg/day curcumin.
 P Value 
Figure Diet Treatment Interaction 
A < 0.0001 < 0.0001 0.2062 
B < 0.0001 0.2536 0.4319 
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Figure 7. Effects of curcumin on plasma concentrations of total cholesterol (A), triglycerides (B) and NEFA (C). 
Values are mean ± SEM, n = 12. Means without a common letter differ, P < 0.05. C, corn starch diet-fed rats; CC5, corn starch diet-fed rats 
supplemented with 5 mg/kg/day curcumin; CC100, corn starch diet-fed rats supplemented with 100 mg/kg/day curcumin; H, high-carbohydrate, 
high-fat diet fed rats; HC5, high-carbohydrate, high-fat diet fed rats supplemented with 5 mg/kg/day curcumin; HC100, high-carbohydrate, 
high-fat diet-fed rats supplemented with 100 mg/kg/day curcumin. 
 P Value 
Figure Diet Treatment Interaction 
A 0.3151 0.2503 0.0796 
B < 0.0001 0.6891 0.9267 
C < 0.0001 0.1855 0.0181 
C 
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3.4 Cardiovascular structure and function 
SBP was measured at 8 and 16 weeks, and this is displayed in Figure 8A. By the beginning of 
the 8th week, HCHF diet feeding induced a significantly higher SPB (approximately 140 
mm/Hg) than the CS diet groups (approximately 115 mm/Hg) (P < 0.0001). At this time point, 
there was no difference between HCHF diet groups and between C and CC5. However, CC100 
was lower than both C and CC5 (P < 0.05). At the end of the 16th week, the SBP of both H and 
HC5 rats had slightly increased from 8 weeks whereas the SPB of the HC100 rats had 
decreased. Overall, H and HC5 rats had a higher SPB than HC100, C, CC5 and CC100 rats (P 
< 0.01), where SBP in HC100, C, CC5 and CC100 rats were not different to each other. 
The diastolic stiffness constant results obtained from the Langendorff heart preparation are 
displayed in Figure 8B. There was no difference in diastolic stiffness constant between all 
groups (P > 0.288). Effects of curcumin on markers of inflammation within the heart for both 
CS diet groups (Figure 9) and HCHF diet groups (Figure 10) is displayed using a hematoxylin 
and eosin stain at a magnification of 20×. There was no observable inflammatory cells within 
the sections of heart for CS diet groups. Whereas there are large aggregations of inflammatory 
cells in the hearts of both H and HC5 rats. Whilst there is greater numbers of inflammatory 
cells within the hearts of HC100 rats, these appears to be less than in H and HC5 rats. 
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Figure 8. Effects of curcumin on change in systolic blood pressure from 8 – 16 weeks 
(A) and diastolic stiffness constant at 16 weeks (B). 
Values are mean ± SEM, n = 8-12. Means without a common letter differ, P < 0.05. C, corn 
starch diet-fed rats; CC5, corn starch diet-fed rats supplemented with 5 mg/kg/day curcumin; 
CC100, corn starch diet-fed rats supplemented with 100 mg/kg/day curcumin; H, high-
carbohydrate, high-fat diet-fed rats; HC5, high-carbohydrate, high-fat diet-fed rats 
supplemented with 5 mg/kg/day curcumin; HC100, high-carbohydrate, high-fat diet-fed rats 
supplemented with 100 mg/kg/day curcumin. Note; significant letters on Figure 8A refer to 
16 week data.
 P Value 
Figure Diet Treatment Interaction 
A – 8 weeks < 0.0001 0.0090 0.3455 
A – 16 weeks 0.0002 0.0137 0.1056 
B 0.2882 0.3809 0.6444 
B 
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A            B                  C 
     
                                 
Figure 9. Effects of curcumin on inflammation in the heart of CS diet groups.  
A-C represent hematoxylin and eosin staining of the heart (20×). C, corn starch diet-fed rats (A); CC5, corn starch diet-fed rats supplemented 
with 5 mg/kg/day curcumin (B); CC100, corn starch diet-fed rats supplemented with 100 mg/kg/day curcumin. 
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A            B                  C 
     
 
 
Figure 10. Effects of curcumin on inflammation in the heart of HCHF diet groups.  
A-C represent hematoxylin and eosin staining of the heart showing inflammatory cells (marked as ‘IC’) (20×). H, high-carbohydrate, high-fat 
diet-fed rats (A); HC5, high-carbohydrate, high-fat diet-fed rats supplemented with 5 mg/kg/day curcumin (B); HC100, high-carbohydrate, 
high-fat diet-fed rats supplemented with 100 mg/kg/day curcumin (C). 
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3.5 Hepatic structure 
Effects of curcumin on fat deposition and inflammation within the liver for CS diet groups (Figure 11) and HCHF diet groups (Figure 12) is 
displayed using a hematoxylin and eosin stain at a magnification of 20×. There appears to be minimal variations between CS diet groups. The 
livers of the HCHF diet groups had considerably more fat deposition than CS diet group livers. Within the HCHF diet groups, there was no 
observable difference between rats for both markers of fat deposition and inflammation. 
 A            B                  C 
     
Figure 11. Effects of curcumin on fat deposition and inflammation in the liver of CS diet groups. 
A-C represent hematoxylin and eosin staining of the liver showing fat deposition (marked as ‘FC’) and inflammatory cells (marked as ‘IC’) 
(20×). C, corn starch diet-fed rats (A); CC5, corn starch diet-fed rats supplemented with 5 mg/kg/day curcumin (B); CC100, corn starch diet-fed 
rats supplemented with 100 mg/kg/day curcumin (C). 
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Figure 12. Effects of curcumin on fat deposition and inflammation in the liver of HCHF diet groups.  
A-C represent hematoxylin and eosin staining of the liver showing fat deposition (marked as ‘FC’) and inflammatory cells (marked as ‘IC’) 
(20×) in H, high-carbohydrate, high-fat diet-fed rats (A); HC5, high-carbohydrate, high-fat diet-fed rats supplemented with 5 mg/kg/day 
curcumin (B); HC100, high-carbohydrate, high-fat diet-fed rats supplemented with 100 mg/kg/day curcumin (C).
FC 
FC 
FC 
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Chapter 4. Discussion 
 
The objective for this study was to determine the effectiveness of low (5 mg/kg/day) and high 
(100 mg/kg/day) doses of curcumin in attenuating symptoms of diet-induced metabolic 
syndrome in rats. The HCHF diet successfully generated a phenotype associated with diet-
induced metabolic syndrome; including obesity, metabolic abnormalities, hypertension and 
ectopic fat deposition in the liver. The findings of this study indicate that the high dose of 
curcumin administered daily to rats with diet-induced metabolic syndrome was able to 
normalise SBP, lower visceral adiposity and reduce inflammation in the heart. Interestingly, 
both the low and high doses of curcumin produced no change in either body weight or total 
body fat content which conflicted with the majority of similar studies (Ding et al., 2016; 
Maithilikarpagaselvi et al., 2016; Shao et al., 2012; Um et al., 2013). 
By the beginning of the 8th week, HCHF diet feeding had induced hypertension in all three of 
the HCHF diet groups, whereas the CS diet groups remained normotensive as in previous 
studies with this model (Bhaswant et al., 2015a; Panchal et al., 2011; Poudyal et al., 2010). 
The high dose of curcumin administered daily from 8 to 16 weeks, led to a decrease in SBP in 
the HC100 group. In contrast, both H and HC5 showed an increase in SBP during this period. 
This appears to be the first diet-induced obesity study in rats that tested if curcumin could 
induce a reversal of hypertension. Previous studies that tested the efficacy of curcumin in 
different hypertensive models, including chronic kidney disease (Correa et al., 2013) and 
chemically induced impairment of vascular function (Nakmareong et al., 2011), did not induce 
a decrease in SBP but instead led to the stabilisation of pre-existing hypertensive blood 
pressure in comparison to controls which continued to increase (Correa et al., 2013; 
Nakmareong et al., 2011). 
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The enhanced effect of curcumin treatment on SBP in this study compared to these other 
studies, despite similar dosages of curcumin (all approximately 100 mg/kg/day), could be 
attributed to the severity of their hypertensive models that may have limited the possibility for 
curcumin to significantly reduce SBP (Correa et al., 2013; Nakmareong et al., 2011). In 
addition, the study using the chemically induced impairment of vascular function had a much 
shorter treatment period (4 weeks compared to the 8 weeks of this study), and a longer time 
frame could have possibly led to a greater reduction in SBP (Nakmareong et al., 2011).  
The mechanisms by which obesity contributes to the development of hypertension are not fully 
elucidated, although elevated renal sympathetic nerve activity (RSNA) has been recognised as 
having a major role in this process (Francischetti and Genelhu, 2007; Hall et al., 2010; Kassab 
et al., 1995). Elevated RSNA impairs the ability of the kidneys to excrete sodium in the urine, 
culminating in increased sodium reabsorption and consequently higher blood pressure to 
maintain sodium balance (Francischetti and Genelhu, 2007). There have been several factors 
implicated in this increase in RSNA including lowered adiponectin levels, visceral adiposity, 
elevated levels of leptin and angiotensin, endothelial dysfunction (controversial as difficult to 
determine whether this occurs before or after hypertension) and oxidative stress (Francischetti 
and Genelhu, 2007; Hall et al., 2010). The ability of curcumin to alleviate SBP in previous 
studies was attributed to an improved antioxidant response, decreased markers of oxidative 
stress and improved endothelial function (Correa et al., 2013; Nakmareong et al., 2011). This 
is supported by the literature, as the antioxidant capacity of curcumin is well documented 
(Malik and Mukherjee, 2014; Naik et al., 2011; Priyadarsini et al., 2003). 
Mitigation of oxidative stress may be a factor in the reduction of SBP observed in this study, 
although this parameter was not measured in this study (unlike Correa et al. and Nakmareong 
et al.), and therefore this claim is speculative. Also, it would be incorrect to assume that this 
is the only mechanism occurring given the multifaceted aspects of both obesity and metabolic 
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syndrome. Visceral adipose tissue has been implicated as having a pathological role in the 
development of hypertension (Atzmon et al., 2002; Faria et al., 2002; Francischetti and 
Genelhu, 2007; Mathieu et al., 2009; Sironi et al., 2004), and this parameter was measured in 
this study. Both the low and high doses of curcumin produced a significant reduction in total 
abdominal fat, in particular retroperitoneal fat, compared to the control rats. A mechanism 
proposed in the link between visceral fat and hypertension is the upregulated secretion of 
angiotensin from adipose tissue depots in the visceral area and subsequent activation of the 
sympathetic nervous system (Atzmon et al., 2002; Ibrahim, 2010). 
In a recent study, a stronger association was found with retroperitoneal fat (the fat surrounding 
the kidneys) and hypertension rather than total visceral fat, suggesting that there are paracrine 
factors involved in this mechanism (Chandra et al., 2014). This may be the reason for the 
greater reduction in SBP observed in the HC100 group, as they had a significantly reduced 
retroperitoneal fat mass. However, the lack of a similar reduction in the SBP of the HC5 rats 
despite their low retroperitoneal fat mass suggests that this hypothesis is not totally correct. 
Future analysis of adiponectin, angiotensin and leptin plasma concentrations as well as 
markers of oxidative stress may provide a greater understanding of the mechanism involved 
in the SBP reduction observed in this study. 
Diastolic stiffness constant from Langendorff heart preparation showed no significant 
difference between groups. In previous studies, HCHF diet feeding consistently produced 
higher diastolic stiffness constant than CS diet controls (Bhaswant et al., 2015a; Bhaswant et 
al., 2015b; Diwan et al., 2013; Panchal et al., 2011). Whilst it is possible that HCHF diet 
feeding did not increase diastolic stiffness, it is also possible that some error contributed to 
this outcome. Further analysis is necessary to confirm this. Histological analysis of heart 
sections using a haematoxylin and eosin stain featured higher aggregations of inflammatory 
cells in HCHF diet groups. Infiltration of inflammatory cells into heart tissue can encourage 
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myocardial (muscular tissue of the heart), endothelial and fibroblast dysfunction leading to 
possible cell death or damage (Yndestad et al., 2006). This suggests that there is damage to 
the heart which may have affected heart function. There was significantly reduced numbers of 
inflammatory cells in the hearts of HC100 rats which in combination with normalisation of 
SBP suggests that there was improved cardiovascular health with 100 mg/kg/day curcumin. 
Visceral obesity has not only been implicated in the development of hypertension, but also in 
NAFLD, type 2 diabetes and inflammation (Cancello et al., 2006; Fontana et al., 2007; Smith 
and Adams, 2011). The significant reduction in visceral adiposity for both curcumin doses in 
this study was not associated with a change in ectopic fat deposition or infiltration of 
inflammatory cells in the liver (Figure 10). This suggests that curcumin had no effect on these 
risk factors for NAFLD or type 2 diabetes (Figure 9 and 10). In previous studies, curcumin 
was able to inhibit or significantly reduce the deposition of fat in the liver (Ding et al., 2016; 
Shao et al., 2012; Um et al., 2013). This reduction in liver fat was accompanied by lowered 
fasting glucose and insulin concentrations and significantly decreased serum cholesterol and 
triglyceride concentrations (Ding et al., 2016; Shao et al., 2012; Um et al., 2013); these 
observations are not seen in this study. 
The lack of significant change in either body weight or total fat mass after curcumin treatment 
in this study was also unexpected given that this was recorded in previous studies (Ding et al., 
2016; Maithilikarpagaselvi et al., 2016; Shao et al., 2012; Um et al., 2013). Weekly body 
weights across the 16-week period for the three HCHF diet groups of rats did not differ 
significantly at any time, and neither did the body weights of the CS diet groups. However, 
the gain in body weight from 8 – 16 weeks as a percentage of total body weight at 8 weeks for 
both HC5 and HC100 was lower than for H, although it was not statistically significant. 
Interestingly, fat mass tended to increase and lean mass tended to decrease from 8 – 16 weeks 
for the low and high curcumin treatment groups for both diets, although not significantly.  
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Out of the four studies compared, oral gavage was used in two studies to deliver dosages of 
80 mg/kg/day (Ding et al., 2016) and 200 mg/kg/day (Maithilikarpagaselvi et al., 2016) and 
the other two studies used modified diets with curcumin at 4 g/kg (Shao et al., 2012) and 0.15% 
diet (Um et al., 2013). The 100 mg/kg/day curcumin treatment group used in this study is 
comparable to the 80 mg/kg/day dose, although it is half that of the 200 mg/kg/day and is 
difficult to compare to the curcumin delivered in diet. Treatment length was longer in three of 
the previous studies (10 – 12 weeks) than the 8 weeks of this study. The division of this study 
into an 8 week pre-treatment period where obesity and symptoms of metabolic syndrome are 
developed followed by curcumin treatment in the remaining 8 weeks to attempt to reverse 
these symptoms is a unique aspect of this study compared to previous studies. In addition, it 
is likely that the HCHF diet used in this study would produce an unhealthier phenotype than 
the diet used in previous studies that were either a high-fat diet or a high-fructose diet (not 
both) (Ding et al., 2016; Maithilikarpagaselvi et al., 2016; Shao et al., 2012; Um et al., 2013).  
It is therefore possible that a longer treatment period or higher dosage may have induced a 
reduction in body weight or total fat, although it is also possible that curcumin (in this delivery 
method) is unable to exert a significant effect in the animal model of obesity used in this 
project. This could be a factor in the other unexpected results observed in this study as there 
was no change in ectopic deposition of fat in the liver, glucose sensitivity and lipid 
concentrations after curcumin treatment. The low bioavailability of curcumin is the major 
limiting factor in its therapeutic use, and perhaps is responsible for the poor effectiveness of 
the 100 mg/kg/day dose of curcumin used in this study (Khalil et al., 2013). In addition, obesity 
induces damage to the gastrointestinal tract which could have compounded this problem of 
poor bioavailability (de La Serre et al., 2010). It is hoped that nanoparticles containing 
curcumin can improve the absorption and delivery of curcumin, and lead to attenuation of 
metabolic syndrome. 
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Chapter 5. Conclusions 
 
The objective for this study was to determine the effectiveness of low and high doses of 
curcumin in attenuating obesity, cardiovascular complications, liver health and metabolic 
abnormalities. The main findings of this study were that the low dose of curcumin did not 
attenuate symptoms of diet-induced obesity, whereas the high dose of curcumin did attenuate 
features of cardiovascular disease, including hypertension and inflammation in the heart. For 
these reasons, the first element of the hypothesis, being the low dose of curcumin (5 
mg/kg/day) orally will have no effects on any of the parameters in obese rats, is accepted. 
However, the second element of the hypothesis, that the high dose of curcumin (100 
mg/kg/day) orally will attenuate diet-induced obesity, changes in heart and liver structure and 
function, and metabolic changes induced by a HCHF diet, is largely rejected. Overall, both the 
low and high orally-administered doses of curcumin were unable to attenuate the effects of 
obesity (excluding reductions in retroperitoneal fat), liver health and metabolic abnormalities, 
which rejected the majority of the hypothesis. This was unexpected as these symptoms of 
metabolic syndrome were successfully attenuated with the use of a similar dose of curcumin 
in previous studies of diet-induced obesity. There were multiple factors that contributed to this 
unexpected result, although the major factor was the poor availability of curcumin that 
prevented the reversal of symptoms of diet-induced metabolic syndrome. 
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Chapter 6. Future Research 
 
Further testing is necessary to strengthen the validity of the health benefits of curcumin 
observed in this study and to greater understand the unexpected results. It would be beneficial 
to examine the extent to the improvement observed in cardiovascular health by curcumin 
intervention. A picrosirius red stain could be used to identity collagen distribution within the 
heart (marker of fibrosis), which would aid in determining the accuracy of the unexpected 
results from the Langendorff experiment. Heart tissue from this study has been stored in 
formalin, and therefore it is possible to conduct this experiment in future. Further, the hearts 
from these experiments have also been stored at –80°C, and molecular biology analysis for 
detecting and quantifying protein and mRNA could be used to assess markers of heart health. 
In addition, given the decreased level of inflammation within the heart tissue observed in 
HC100 rats, it could be beneficial to test for plasma concentrations of adiponectin and 
inflammatory biomarkers. 
It still remains to be seen whether the nanoparticles containing curcumin will produce 
improved health benefits over curcumin, as hypothesised. There was no indication that 
curcumin could attenuate liver structure and function, and metabolic abnormalities associated 
with metabolic syndrome. If nanoparticles containing curcumin are able to produce significant 
improvement to symptoms of metabolic syndrome, then further analysis of plasma enzymes 
of liver health, Western blot analysis and microbial analysis of faecal samples will be 
conducted to be used as a comparison point for those results. Overall, this future sister study 
with curcumin nanoparticles to improve its bioavailability would certainly be able to answer 
if the increased bioavailability of curcumin can attenuate diet-induced metabolic syndrome. 
 
 
53 
 
References 
 
Ahn, J., Lee, H., Kim, S., and Ha, T. (2010). Curcumin-induced suppression of adipogenic 
differentiation is accompanied by activation of Wnt/β-catenin signaling. American Journal of 
Physiology-Cell Physiology 298, C1510-C1516. 
Ak, T., and Gülçin, I. (2008). Antioxidant and radical scavenging properties of curcumin. 
Chemico-Biological Interactions 174, 27-37. 
Alberti, K., Eckel, R., Grundy, S., Zimmet, P., Cleeman, J., Donato, K., Fruchart, J., James, 
W., Loria, C., and Smith, S. (2009). Harmonizing the metabolic syndrome: a joint interim 
statement of the International Diabetes Federation Task Force on Epidemiology and 
Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World 
Heart Federation; International Atherosclerosis Society; and International Association for the 
Study of Obesity. Circulation 120, 1640-1645. 
Alberti, K., Zimmet, P., and Shaw, J. (2006). Metabolic syndrome—a new world-wide 
definition. A consensus statement from the International Diabetes Federation.  (Wiley-
Blackwell), pp. 469-480. 
Amolins, M., Peterson, L., and Blagg, B. (2009). Synthesis and evaluation of electron-rich 
curcumin analogues. Bioorganic & Medicinal Chemistry 17, 360-367. 
Anand, P., Kunnumakkara, A.B., Newman, R.A., and Aggarwal, B.B. (2007). Bioavailability 
of curcumin: problems and promises. Molecular Pharmacology 4, 807-818. 
54 
 
Antony, B., Merina, B., Iyer, V., Judy, N., Lennertz, K., and Joyal, S. (2008). A pilot cross-
over study to evaluate human oral bioavailability of BCM-95® CG (BiocurcumaxTM), a 
novel bioenhanced preparation of curcumin. Indian Journal of Pharmaceutical Sciences 70, 
445. 
Ärnlöv, J., Ingelsson, E., Sundström, J., and Lind, L. (2010). Impact of body mass index and 
the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. 
Circulation 121, 230-236. 
Atzmon, G., Yang, X., Muzumdar, R., Ma, X., Gabriely, I., and Barzilai, N. (2002). 
Differential gene expression between visceral and subcutaneous fat depots. Hormone and 
Metabolic Research 34, 622-628. 
Baum, L., Cheung, S., Mok, V., Lam, L., Leung, V., Hui, E., Ng, C., Chow, M., Ho, P., Lam, 
S., et al. (2007). Curcumin effects on blood lipid profile in a 6-month human study. 
Pharmacological Research 56, 509-514. 
Begum, A., Jones, M., Lim, G., Morihara, T., Kim, P., Heath, D., Rock, C., Pruitt, M., Yang, 
F., Hudspeth, B., et al. (2008). Curcumin structure-function, bioavailability, and efficacy in 
models of neuroinflammation and Alzheimer's disease. Journal of Pharmacology and 
Experimental Therapeutics 326, 196-208. 
Bentzon, J., Otsuka, F., Virmani, R., and Falk, E. (2014). Mechanisms of plaque formation 
and rupture. Circulation Research 114, 1852-1866. 
55 
 
Bhaswant, M., Fanning, K., Netzel, M., Mathai, M., Panchal, S., and Brown, L. (2015a). 
Cyanidin 3-glucoside improves diet-induced metabolic syndrome in rats. Pharmacological 
Research 102, 208-217. 
Bhaswant, M., Poudyal, H., Mathai, M., Ward, L., Mouatt, P., and Brown, L. (2015b). Green 
and black cardamom in a diet-induced rat model of metabolic syndrome. Nutrients 7, 7691-
7707. 
Brown, L., Poudyal, H., and Panchal, S. (2015). Functional foods as potential therapeutic 
options for metabolic syndrome. Obesity Reviews 16, 914-941. 
Cancello, R., Tordjman, J., Poitou, C., Guilhem, G., Bouillot, J., Hugol, D., Coussieu, C., 
Basdevant, A., Hen, A., Bedossa, P., et al. (2006). Increased infiltration of macrophages in 
omental adipose tissue Is associated with marked hepatic lesions in morbid human obesity. 
Diabetes 55, 1554-1561. 
Cannon, B., and Nedergaard, J. (2004). Brown adipose tissue: function and physiological 
significance. Physiological Reviews 84, 277-359. 
CDC (2015). Adult obesity facts. [Accessed March 2016]. 
Chandra, A., Neeland, I., Berry, J., Ayers, C., Rohatgi, A., Das, S., Khera, A., McGuire, D., 
de Lemos, J., and Turer, A. (2014). The relationship of body mass and fat distribution with 
incident hypertension: observations from the Dallas Heart Study. Journal of the American 
College of Cardiology 64, 997-1002. 
56 
 
Cheng, A.-L., Hsu, C.-H., Lin, J.-K., Hsu, M.-M., Ho, Y.-F., Shen, T.-S., Ko, J.-Y., Lin, J.-
T., Lin, B.-R., and Ming-Shiang, W. (2001). Phase I clinical trial of curcumin, a 
chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer 
Research 21, 2895-2900. 
Choe, S., Huh, J., Hwang, I., Kim, J., and Kim, J. (2016). Adipose tissue remodeling: its role 
in energy metabolism and metabolic disorders. Frontiers in Endocrinology 7, 30. 
Chuengsamarn, S., Rattanamongkolgul, S., Phonrat, B., Tungtrongchitr, R., and Jirawatnotai, 
S. (2014). Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid 
extract: a randomized controlled trial. The Journal of Nutritional Biochemistry 25, 144-150. 
Correa, F., Buelna-Chontal, M., Hernández-Reséndiz, S., R. García-Niño, W., J. Roldán, F., 
Soto, V., Silva-Palacios, A., Amador, A., Pedraza-Chaverrí, J., Tapia, E., et al. (2013). 
Curcumin maintains cardiac and mitochondrial function in chronic kidney disease. Free 
Radical Biology and Medicine 61, 119-129. 
Crespo, J., Cayón, A., Fernández‐Gil, P., Hernández‐Guerra, M., Mayorga, M., Domínguez‐
Díez, A., Fernández‐Escalante, J., and Pons‐Romero, F. (2001). Gene expression of tumor 
necrosis factor α and TNF‐receptors, p55 and p75, in nonalcoholic steatohepatitis patients. 
Hepatology 34, 1158-1163. 
de La Serre, C., Ellis, C., Lee, J., Hartman, A., Rutledge, J., and Raybould, H. (2010). 
Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut 
microbiota and gut inflammation. American Journal of Physiology - Gastrointestinal and 
Liver Physiology 299, G440-G448. 
57 
 
Ding, L., Li, J., Song, B., Xiao, X., Zhang, B., Qi, M., Huang, W., Yang, L., and Wang, Z. 
(2016). Curcumin rescues high fat diet-induced obesity and insulin sensitivity in mice 
through regulating SREBP pathway. Toxicology and Applied Pharmacology, 99-101. 
Diwan, V., Poudyal, H., and Brown, L. (2013). Piperine attenuates cardiovascular, liver and 
metabolic changes in high carbohydrate, high fat-fed rats. Cell Biochemistry and Biophysics 
67, 297-304. 
Ejaz, A., Wu, D., Kwan, P., and Meydani, M. (2009). Curcumin inhibits adipogenesis in 3T3-
L1 adipocytes and angiogenesis and obesity in C57/BL mice. The Journal of Nutrition 139, 
919-925. 
El-Sayed Moustafa, J., and Froguel, P. (2013). From obesity genetics to the future of 
personalized obesity therapy. Nature Reviews Endocrinology 9, 402-413. 
Encinosa, W., Bernard, D., Steiner, C., and Chen, C. (2005). Use and costs of bariatric 
surgery and prescription weight-loss medications. Health Affairs 24, 1039-1046. 
Expert Panel on Detection, E., and Treatment of High Blood Cholesterol in Adults (2001). 
Executive summary of the Third Report of the National Cholesterol Education Program 
(NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in 
adults (Adult Treatment Panel III). Journal of the American Medical Association 285, 2486. 
Faria, A., Ferreira, S., G, R., and Zanella, M. (2002). Impact of visceral fat on blood pressure 
and insulin sensitivity in hypertensive obese women. Obesity Research 10, 1203-1206. 
58 
 
Faust, I., Johnson, P., Stern, J., and Hirsch, J. (1978). Diet-induced adipocyte number 
increase in adult rats: a new model of obesity. American Journal of Physiology - 
Endocrinology and Metabolism 235, E279. 
Ferguson, B., Nam, H., and Morrison, R. (2016). Curcumin inhibits 3T3-L1 preadipocyte 
proliferation by mechanisms involving post-transcriptional p27 regulation. Biochemistry and 
Biophysics Reports 5, 16-21. 
Fontana, L., Eagon, J., Trujillo, M., Scherer, P., and Klein, S. (2007). Visceral fat adipokine 
secretion is associated with systemic inflammation in obese humans. Diabetes 56, 1010-1013. 
Francischetti, E., and Genelhu, V. (2007). Obesity–hypertension: an ongoing pandemic. 
International Journal of Clinical Practice 61, 269-280. 
Freedman, D., Khan, L., Dietz, W., Srinivasan, S., and Berenson, G. (2001). Relationship of 
childhood obesity to coronary heart disease risk factors in adulthood: the Bogalusa Heart 
Study. Pediatrics 108, 712-718. 
Gao, S., Zhou, J., Liu, N., Wang, L., Gao, Q., Wu, Y., Zhao, Q., Liu, P., Wang, S., Liu, Y., et 
al. (2015). Curcumin induces M2 macrophage polarization by secretion IL-4 and/or IL-13. 
Journal of Molecular and Cellular Cardiology 85, 131-139. 
Gloy, V., Briel, M., Bhatt, D., Kashyap, S., Schauer, P., Mingrone, G., Bucher, H., and 
Nordmann, A. (2013). Bariatric surgery versus non-surgical treatment for obesity: a 
systematic review and meta-analysis of randomised controlled trials. British Medical Journal 
347, f5934. 
59 
 
Graziose, R., Lila, M., and Raskin, I. (2010). Merging traditional chinese medicine with 
modern drug discovery technologies to find novel drugs and functional foods. Current Drug 
Discovery Technologies 7, 2-12. 
Grundy, S., Brewer, H., Cleeman, J., Smith, S., and Lenfant, C. (2004). Definition of 
metabolic syndrome report of the National Heart, Lung, and Blood Institute/American Heart 
Association Conference on scientific issues related to definition. Circulation 109, 433-438. 
Hajer, G., van Haeften, T., and Visseren, F. (2008). Adipose tissue dysfunction in obesity, 
diabetes, and vascular diseases. European Heart Journal 29, 2959-2971. 
Hall, J., da Silva, A., do Carmo, J., Dubinion, J., Hamza, S., Munusamy, S., Smith, G., and 
Stec, D. (2010). Obesity-induced hypertension: role of sympathetic nervous system, leptin, 
and melanocortins. Journal of Biological Chemistry 285, 17271-17276. 
Hanson, M., Fareed, M., Argenio, S., Agunwamba, A., and Hanson, T. (2013). Coronary 
artery disease. Primary Care: Clinics in Office Practice 40, 1-16. 
Hsu, C., Wu, C., Huang, S., and Yen, G. (2009). Phenolic compounds rutin and o-coumaric 
acid ameliorate obesity induced by high-fat diet in rats. Journal of Agricultural and Food 
Chemistry 57, 425-431. 
Huang, P. (2009). eNOS, metabolic syndrome and cardiovascular disease. Trends in 
Endocrinology and Metabolism 20, 295-302. 
60 
 
Ibrahim, M. (2010). Subcutaneous and visceral adipose tissue: structural and functional 
differences. Obesity Reviews 11, 11-18. 
Jo, J., Gavrilova, O., Pack, S., Jou, W., Mullen, S., Sumner, A., Cushman, S., and Periwal, V. 
(2009). Hypertrophy and/or hyperplasia: dynamics of adipose tissue growth. PLOS 
Computational Biology 5, e1000324. 
Kang, J., Tsuyoshi, G., Han, I., Kawada, T., Kim, Y., and Yu, R. (2010). Dietary capsaicin 
reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat 
diet. Obesity 18, 780-787. 
Kaser, S., Moschen, A., Cayon, A., Kaser, A., Crespo, J., Pons-Romero, F., Ebenbichler, C., 
Patsch, J., and Tilg, H. (2005). Adiponectin and its receptors in non-alcoholic steatohepatitis. 
Gut 54, 117-121. 
Kassab, S., Kato, T., Wilkins, F., Chen, R., Hall, J., and Granger, J. (1995). Renal 
denervation attenuates the sodium retention and hypertension associated With obesity. 
Hypertension 25, 893-897. 
Kassi, E., Pervanidou, P., Kaltsas, G., and Chrousos, G. (2011). Metabolic syndrome: 
definitions and controversies. BioMed Central Medicine 9, 1. 
Khalil, N., do Nascimento, T., Casa, D., Dalmolin, L., de Mattos, A., Hoss, I., Romano, M., 
and Mainardes, R. (2013). Pharmacokinetics of curcumin-loaded PLGA and PLGA–PEG 
blend nanoparticles after oral administration in rats. Colloids and Surfaces B: Biointerfaces 
101, 353-360. 
61 
 
Kim, C., Le, T., Chen, C., Cheng, J., and Kim, K. (2011). Curcumin inhibits adipocyte 
differentiation through modulation of mitotic clonal expansion. The Journal of Nutritional 
Biochemistry 22, 910-920. 
Kirschweng, B., Tátraaljai, D., Földes, E., and Pukánszky, B. (2015). Efficiency of curcumin, 
a natural antioxidant, in the processing stabilization of PE: Concentration effects. Polymer 
Degradation and Stability 118, 17-23. 
Kumari, A., Yadav, S., and Yadav, S. (2010). Biodegradable polymeric nanoparticles based 
drug delivery systems. Colloids and Surfaces B: Biointerfaces 75, 1-18. 
Li, Z., Maglione, M., Tu, W., Mojica, W., Arterburn, D., Shugarman, L., Hilton, L., Suttorp, 
M., Solomon, V., and Shekelle, P. (2005). Meta-analysis: pharmacologic treatment of 
obesity. Annals of Internal Medicine 142, 532-546. 
Liu, C., and Chang, F. (2011). Development and characterization of eucalyptol 
microemulsions for topic delivery of curcumin. Chemical and Pharmaceutical Bulletin 59, 
172-178. 
Lone, J., Choi, J., Kim, S., and Yun, J. (2016). Curcumin induces brown fat-like phenotype in 
3T3-L1 and primary white adipocytes. The Journal of Nutritional Biochemistry 27, 193-202. 
Lusis, A. (2000). Atherosclerosis. Nature 407, 233-241. 
Maithilikarpagaselvi, N., Sridhar, M., Swaminathan, R., and Zachariah, B. (2016). Curcumin 
prevents inflammatory response, oxidative stress and insulin resistance in high fructose fed 
62 
 
male Wistar rats: Potential role of serine kinases. Chemico-Biological Interactions 244, 187-
194. 
Malik, P., and Mukherjee, T. (2014). Structure-function elucidation of antioxidative and 
prooxidative activities of the polyphenolic compound curcumin. Chinese Journal of Biology 
2014. 
Mathieu, P., Poirier, P., Pibarot, P., Lemieux, I., and Després, J. (2009). Visceral obesity. The 
Link Among Inflammation, Hypertension, and Cardiovascular Disease 53, 577-584. 
Maury, E., and Brichard, S. (2010). Adipokine dysregulation, adipose tissue inflammation 
and metabolic syndrome. Molecular and Cellular Endocrinology 314, 1-16. 
McGill, A. (2014). Causes of metabolic syndrome and obesity-related co-morbidities part 1. 
A composite unifying theory review of human-specific co-adaptations to brain energy 
consumption. Archives of Public Health 72, 30. 
Naik, S., Thakare, V., and Patil, S. (2011). Protective effect of curcumin on experimentally 
induced inflammation, hepatotoxicity and cardiotoxicity in rats: Evidence of its antioxidant 
property. Experimental and Toxicologic Pathology 63, 419-431. 
Nakmareong, S., Kukongviriyapan, U., Pakdeechote, P., Donpunha, W., Kukongviriyapan, 
V., Kongyingyoes, B., Sompamit, K., and Phisalaphong, C. (2011). Antioxidant and vascular 
protective effects of curcumin and tetrahydrocurcumin in rats with l-NAME-induced 
hypertension. Naunyn-Schmiedeberg's Archives of Pharmacology 383, 519. 
63 
 
Ochner, C., Tsai, A., Kushner, R., and Wadden, T. (2015). Treating obesity seriously: when 
recommendations for lifestyle change confront biological adaptations. The Lancet Diabetes 
and Endocrinology 3, 232-234. 
Panahi, Y., Hosseini, M., Khalili, N., Naimi, E., Soflaei, S., Majeed, M., and Sahebkar, A. 
(2016). Effects of supplementation with curcumin on serum adipokine concentrations: a 
randomized controlled trial. Nutrition. 
Panchal, S., Poudyal, H., Iyer, A., Nazer, R., Alam, A., Diwan, V., Kauter, K., Sernia, C., 
Campbell, F., and Ward, L. (2011). High-carbohydrate, high-fat diet–induced metabolic 
syndrome and cardiovascular remodeling in rats. Journal of Cardiovascular Pharmacology 57, 
611-624. 
Panchal, S.K., and Brown, L. (2011). Rodent models for metabolic syndrome research. 
BioMed Research International 2011. 
Paschos, P., and Paletas, K. (2009). Non alcoholic fatty liver disease and metabolic 
syndrome. Hippokratia 13, 9-19. 
Poudyal, H., Panchal, S., and Brown, L. (2010). Comparison of purple carrot juice and β-
carotene in a high-carbohydrate, high-fat diet-fed rat model of the metabolic syndrome. 
British Journal of Nutrition 104, 1322-1332. 
Prasad, S., Gupta, S., Tyagi, A., and Aggarwal, B. (2014). Curcumin, a component of golden 
spice: From bedside to bench and back. Biotechnology Advances 32, 1053-1064. 
64 
 
Priyadarsini, K., Maity, D., Naik, G., Kumar, M., Unnikrishnan, M., Satav, J., and Mohan, H. 
(2003). Role of phenolic O-H and methylene hydrogen on the free radical reactions and 
antioxidant activity of curcumin. Free Radical Biology and Medicine 35, 475-484. 
Promrat, K., Kleiner, D., Niemeier, H., Jackvony, E., Kearns, M., Wands, J., Fava, J., and 
Wing, R. (2010). Randomized controlled trial testing the effects of weight loss on 
nonalcoholic steatohepatitis. Hepatology 51, 121-129. 
Rahmatullah, M., Noman, A., Hossan, S., Rashid, M., Rahman, T., Chowdhury, M., and 
Jahan, R. (2009). A survey of medicinal plants in two areas of Dinajpur district, Bangladesh 
including plants which can be used as functional foods. American Eurasian Journal of 
Sustainable Agriculture 3, 862-876. 
Rates, S. (2001). Plants as source of drugs. Toxicon 39, 603-613. 
Rinwa, P., and Kumar, A. (2012). Piperine potentiates the protective effects of curcumin 
against chronic unpredictable stress-induced cognitive impairment and oxidative damage in 
mice. Brain Research 1488, 38-50. 
Ritchie, S., and Connell, J. (2007). The link between abdominal obesity, metabolic syndrome 
and cardiovascular disease. Nutrition, Metabolism and Cardiovascular Diseases 17, 319-326. 
Sandur, S., Pandey, M., Sung, B., Ahn, K., Murakami, A., Sethi, G., Limtrakul, P., Badmaev, 
V., and Aggarwal, B. (2007). Curcumin, demethoxycurcumin, bisdemethoxycurcumin, 
tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-
65 
 
proliferative responses through a ROS-independent mechanism. Carcinogenesis 28, 1765-
1773. 
Sattar, N., Forrest, E., and Preiss, D. (2014). Non-alcoholic fatty liver disease. British 
Medical Journal 349. 
Sergent, T., Vanderstraeten, J., Winand, J., Beguin, P., and Schneider, Y. (2012). Phenolic 
compounds and plant extracts as potential natural anti-obesity substances. Food Chemistry 
135, 68-73. 
Shabalina, I., Petrovic, N., de Jong, J., Kalinovich, A., Cannon, B., and Nedergaard, J. 
(2013). UCP1 in brite/beige adipose tissue mitochondria Is functionally thermogenic. Cell 
Reports 5, 1196-1203. 
Shao, W., Yu, Z., Chiang, Y., Yang, Y., Chai, T., Foltz, W., Lu, H., Fantus, I., and Jin, T. 
(2012). Curcumin prevents high fat diet induced insulin resistance and obesity via attenuating 
lipogenesis in liver and inflammatory pathway in adipocytes. Public Library of Science One 
7, e28784. 
Sironi, A., Gastaldelli, A., Mari, A., Ciociaro, D., Postano, V., Buzzigoli, E., Ghione, S., 
Turchi, S., Lombardi, M., and Ferrannini, E. (2004). Visceral fat in hypertension influence on 
insulin resistance and  β-cell function. Hypertension 44, 127-133. 
Smeerdijk, J., Jovic, M., Hutchins, D., Petre, T., and Lee, J. (2015). Weighing the cost of 
obesity: a case for action.  (PricewaterhouseCoopers International Limited). 
66 
 
Smith, B., and Adams, L. (2011). Non-alcoholic fatty liver disease. Critical Reviews in 
Clinical Laboratory Sciences 48, 97-113. 
Sun, K., Kusminski, C., and Scherer, P. (2011a). Adipose tissue remodeling and obesity. The 
Journal of Clinical Investigation 121, 2094-2101. 
Sun, K., Kusminski, C.M., and Scherer, P.E. (2011b). Adipose tissue remodeling and obesity. 
The Journal of Clinical Investigation 121, 2094-2101. 
Tankó, L., Bruun, J., Alexandersen, P., Bagger, Y., Richelsen, B., Christiansen, C., and 
Larsen, P. (2004). Novel associations between bioavailable estradiol and adipokines in 
elderly women with different phenotypes of obesity. Implications for Atherogenesis 110, 
2246-2252. 
Tchernof, A., and Després, J. (2013). Pathophysiology of human visceral obesity: an update. 
Physiological Reviews 93, 359-404. 
Tilg, H., and Moschen, A. (2010). Evolution of inflammation in nonalcoholic fatty liver 
disease: the multiple parallel hits hypothesis. Hepatology 52, 1836-1846. 
Trayhurn, P. (2013). Hypoxia and adipose tissue function and dysfunction in obesity. 
Physiological Reviews 93, 1-21. 
Um, M., Hwang, K., Ahn, J., and Ha, T. (2013). Curcumin attenuates diet‐induced hepatic 
steatosis by activating AMP‐activated protein kinase. Basic and Clinical Pharmacology and 
Toxicology 113, 152-157. 
67 
 
Wang, S., Wang, X., Ye, Z., Xu, C., Zhang, M., Ruan, B., Wei, M., Jiang, Y., Zhang, Y., 
Wang, L., et al. (2015). Curcumin promotes browning of white adipose tissue in a 
norepinephrine-dependent way. Biochemical and Biophysical Research Communications 
466, 247-253. 
Weisberg, S., Leibel, R., and Tortoriello, D. (2008). Dietary curcumin significantly improves 
obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology 
149, 3549-3558. 
Wentzel, J., Chatzizisis, Y., Gijsen, F., Giannoglou, G., Feldman, C., and Stone, P. (2012). 
Endothelial shear stress in the evolution of coronary atherosclerotic plaque and vascular 
remodelling: current understanding and remaining questions. Cardiovascular Research 96, 
234-243. 
Westerterp-Plantenga, M., Diepvens, K., Joosen, A., Bérubé-Parent, S., and Tremblay, A. 
(2006). Metabolic effects of spices, teas, and caffeine. Physiology and Behavior 89, 85-91. 
WHO (2014). The top 10 causes of death. [Accessed November 2016]. 
WHO (2015). Obesity and overweight. [Accessed February 2016]. 
Wilken, R., Veena, M., Wang, M., and Srivatsan, E. (2011). Curcumin: A review of anti-
cancer properties and therapeutic activity in head and neck squamous cell carcinoma. 
Molecular Cancer 10, 1. 
68 
 
Wing, R., Lang, W., Wadden, T., Safford, M., Knowler, W., Bertoni, A., Hill, J., Brancati, F., 
Peters, A., and Wagenknecht, L. (2011). Benefits of modest weight loss in improving 
cardiovascular risk factors in overweight and obese individuals with type 2 Diabetes. 
Diabetes Care 34, 1481-1486. 
Wood, I., de Heredia, F., Wang, B., and Trayhurn, P. (2009). Cellular hypoxia and adipose 
tissue dysfunction in obesity. Proceedings of the Nutrition Society 68, 370-377. 
Yndestad, A., Damås, J., Øie, E., Ueland, T., Gullestad, L., and Aukrust, P. (2006). Systemic 
inflammation in heart failure–the whys and wherefores. Heart Failure Reviews 11, 83-92. 
Zhou, H., Beevers, C., and Huang, S. (2011). Targets of curcumin. Current Drug Targets 12, 
332-347. 
 
